Stockwinners Market Radar for December 02, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:07 EST Cathie Wood's ARK Investment bought 281.4K shares of Square on Thursday

21:05 EST Cathie Wood's ARK Investment bought 370.4K shares of Roblox on Thursday

20:24 EST Tutor Perini announces two projects collectively valued at $218.8M - Tutor Perini has been awarded a firm fixed-price contract valued at $161.8M by the Naval Facilities Engineering Systems Command, Pacific Division for site development and construction of an aircraft parking apron and taxiway at the Tinian International Airport, Tinian, Commonwealth of the Northern Mariana Islands. Initial mobilization to the island will begin in April 2022, with work to commence in June and be completed by October 2025. The project will be included in the Company's fourth-quarter 2021 backlog. In addition, the Black Construction-Tutor Perini JV has been awarded a firm fixed-price contract valued at $57.0M by NAVFAC Pacific for the J-015 Enlisted Dining Facility project at Camp Blaz Marine Corps Base Guam. The project will be included in the Company's fourth-quarter 2021 backlog.

19:30 EST Hillenbrand raises quarterly dividend to 21.75c from 21.50c per share - The dividend is payable December 30, 2021, to shareholders of record at the close of business on December 17, 2021.

19:20 EST Longeveron's Allogeneic MSCs granted FDA orphan designation - Longeveron's Allogeneic bone marrow-derived mesenchymal stromal cells, or MSCs, are granted FDA orphan designation as a treatment of Hypoplastic Left Heart Syndrome, according to a post to the agency's website. Reference Link

18:34 EST Nucor raises quarterly dividend 23%, announces new $4B share repurchase program - The Board of Directors of Nucor announced the increase of its regular quarterly cash dividend on Nucor's common stock to 50c per share. This cash dividend is payable on February 11, 2022 to stockholders of record on December 31, 2021 and is Nucor's 195th consecutive quarterly cash dividend. In a separate action, Nucor's Board of Directors approved the repurchase of up to $4B of the company's outstanding common stock. This new authorization replaces the previously authorized $3B repurchase program, which was terminated by the Board of Directors in connection with the approval of the new authorization, under which approximately $2.33B of the company's common stock had been repurchased from its authorization in May through December 1. The new share repurchase authorization is discretionary and has no expiration date.

17:49 EST Minerva Surgical jumps over 10% to $6.40 after Q3 results

17:47 EST Smith & Wesson Brands drops 14% to $19.60 after Q2 results miss estimates

17:18 EST PetIQ CEO buys $1.0M in common stock - In a regulatory filing, PetIQ disclosed that its CEO McCord Christensen bought 50K shares of common stock on December 1st in a total transaction size of $1.0M, boosting his stake by over 700%. PetIQ shares are up 1.6% after-hours at $21.59.

17:01 EST Dril-Quip appoints Kyle McClure as CFO - Dril-Quip announced that its board of directors has appointed Kyle McClure as its VP and CFO effective January 1, 2022. McClure has most recently served as CFO of Airswift, a global workforce solutions company, from June 2019 until December 2021.

16:58 EST Sinclair Broadcast announces multi-year renewal of digital rights pact with NHL - Sinclair Broadcast Group announced that its wholly-owned subsidiary, Diamond Sports Group, has entered into a multi-year renewal of its digital and outer market distribution rights agreement with the National Hockey League. Under the agreement, DSG's Bally Sports Regional Networks are permitted to offer streaming content, including live games, on an authenticated and direct-to-consumer basis, to the local territories of 12 NHL teams. The agreement was expanded to allow post-game highlights on Sinclair's digital news platforms, alternative feeds, and use of the NHL's proprietary Puck and Player Tracking data in the broadcasts of the games.

16:55 EST ACV Auctions director sells $2.15M in common stock - In a regulatory filing, ACV Auctions disclosed that its director Robert Goodman sold 102K shares of common stock in a total transaction size of $2.15M on November 30th, reducing his stake by about 19%.

16:50 EST Eastman Chemical announces 10% dividend increase - The board of Eastman Chemical Company has declared a quarterly cash dividend of 76c per share on the company's common stock, a 10% increase from 69c per share. The dividend is payable January 7, 2022, to stockholders of record as of December 15, 2021.

16:38 EST Marvell jumps 10% to $78.27 after Q3 results, Q4 guidance beat estimates

16:36 EST Werner to integrate with Decisiv platform to expand repair network - Werner Enterprises "has announced a new data integration with the Decisiv Service Relationship Management platform into its Werner EDGE Application Programming Interface powered applications. Werner is the first carrier to implement this integration, which aims to expand Werner's repair network to more than 13,000 repair shops in the company's vendor network. Werner currently has integrated with over 33 percent of its comprehensive vendor network for improved efficiencies as part of an ongoing innovation strategy. Through this integration, Werner now has immediate access to 5,000 repair shops through the Decisiv network."

16:32 EST DocuSign drops 23% to $179.60 after Q4 revenue guidance misses estimates

16:32 EST Owens Corning raises quarterly dividend 35% to 35c per share - Owens Corning announced that its Board of Directors has declared a quarterly cash dividend of 35c per common share, a 35% increase compared with the prior quarterly dividend. The dividend will be payable on January 21, 2022, to shareholders of record as of January 7, 2022. "Owens Corning has delivered outstanding results and continued strong cash flow generation," said Chair and Chief Executive Officer Brian Chambers. "The dividend increase demonstrates our confidence in the earnings power of the company, as well as our commitment to returning cash to shareholders over time."

16:31 EST CNA Financial names Scott Lindquist CFO - CNA announced the appointment of Scott Lindquist as Executive Vice President and Chief Financial Officer. Scott will join CNA on January 10, 2022 and will assume the duties of Chief Financial Officer following the filing of the company's 2021 annual report on Form 10-K. Scott will succeed Larry Haefner, who has served as Interim Chief Financial Officer since September 2021. He will report to Dino E. Robusto, Chairman and Chief Executive Officer at CNA. Scott and Larry will work together through the first quarter of 2022 to ensure a seamless transition. "Scott brings three decades of finance and leadership experience to this role," Robusto said. "In addition, he has a proven track record as a Chief Financial Officer of driving strategy, execution and disciplined governance with his deep knowledge of the P&C industry." Scott most recently served as the Chief Financial Officer at Farmers Group.

16:30 EST Ecolab raises quarterly dividend 6% to 51c per share - To be paid January 18, 2022, to shareholders of record at the close of business on December 14, 2021.

16:19 EST Ulta Beauty up 6% after beat and raise report - Ulta shares are up $24.53, or 6%, to $408.17 in after-hours trading.

16:18 EST Smith & Wesson Brands reports Q2 gross margin 44.3% vs. 40.6% last year - Deana McPherson, Executive Vice President and CFO, commented, "Our second quarter results continue to demonstrate our ability to react to the changing needs of the market. We delivered a 370 basis point increase in gross margin that more than offset a 7.3% decrease in revenue compared with the prior year second quarter. Although below the prior year, the current quarter's revenue represents a two-year compounded growth rate of over 140% and is one of the many examples of how our flexible manufacturing model allows our business to return impressive financial performance in both increasing and decreasing demand environments. Inventory in the channel has finally been restored in many of our product categories and we continue to replenish our internal inventories. We believe that our strong balance sheet, impressive product array, and commitment to be the market leader will enable us to continue to invest in our business and capture market share, as we fulfill our commitment to return capital to our stockholders. Our Board of Directors has again authorized our $0.08 per share quarterly dividend, which will be paid to stockholders of record on December 16th with payment to be made on January 4th."

16:15 EST Zillow approves $750M share repurchase program - Zillow Group authorized the repurchase of up to $750M of its Class A common stock, Class C capital stock or a combination of both. The share repurchase program, which has been approved by Zillow Group's Board of Directors, allows for repurchases of up to $750M of the Company's Class A common stock, Class C capital stock or a combination of both. The timing and actual number of shares repurchased will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions and other general business considerations.

16:13 EST Federal Realty announces holding company reorganization - Federal Realty Investment Trust announced that it intends to complete a holding company reorganization that would structure the company as an Umbrella Partnership Real Estate Investment Trust, or UPREIT. In the Reorganization, a new holding company would become the publicly traded parent company while the current real estate investment trust would convert to a limited partnership controlled by the holding company. The holding company reorganization is expected to be effective as of January 1, 2022, and the conversion of the existing Federal Realty to a limited partnership is expected to be effective on January 4, 2022. When the Reorganization is complete, the holding company will be a real estate investment trust named Federal Realty Investment Trust, just as the company is today, and its common shares and Series C depositary shares are expected to continue to trade on the NYSE under the symbols FRT and FRT/C, respectively.

16:12 EST CTO Realty Growth acquires Beaver Creek Crossing in North Carolina for $70.5M - CTO Realty Growth announced the acquisition of Beaver Creek Crossings, a 320,600 square foot multi-tenant retail property in the Apex submarket of Raleigh, North Carolina for $70.5M. The purchase price represents a going-in cap rate within the range of the company's guidance for initial cash yields. The company purchased the property through a 1031 like-kind exchange using $66.7M of restricted cash generated from the company's previously completed property dispositions, available cash, and draws from the company's unsecured revolving credit facility.

16:11 EST White Mountains names Liam Caffrey as CFO, effective March 1, 2022 - White Mountains announced that Liam Caffrey will become its CFO on March 1, 2022. Caffrey currently serves as a consultant to a subsidiary of the company. Previously, Caffrey spent nine years at Aon plc, most recently as CEO of Aon Affinity and global CFO of Aon Risk Solutions. Before Aon, Caffrey was a partner with McKinsey & Company. Reid Campbell, White Mountains's current CFO, will become President of White Mountains on March 1, 2022 and will serve in that role until his retirement in February 2024. In his role as President, Campbell will maintain all his current executive duties other than his responsibilities as CFO. In addition, Campbell will continue to serve as a director of Build America Mutual Assurance Company and Ark Insurance Holdings Limited.

16:09 EST Tilly's plans to open 15-20 new stores in 2022 - The company states: "During FY22, we currently plan to open approximately 15 to 20 new stores within existing markets, primarily in California, Texas and the Northeast, assuming we are able to negotiate what we believe to be acceptable lease economics. We expect our total capital expenditures for fiscal 2022 to be in the range of approximately $25 million to $30 million, inclusive of our new store plans, investments in website and mobile app upgrades, distribution efficiencies, and other information technology infrastructure investments."

16:09 EST Tilly's says Q4 total comparable net sales increased 19.6% through November - The company states: "Last year's fourth quarter was the first full period since the pandemic began in which the Company was fully operational. Total comparable net sales through November 30, 2021, increased by 19.6% compared to last year, with comparable net sales increases from physical stores of 27.6% and from e-commerce of 3.9%."

16:05 EST Lyft names Elaine Paul as new CFO - Lyft announced that Elaine Paul has been named chief financial officer, effective January 3, 2022. Paul replaces Brian Roberts, who is stepping down but will remain an advisor until June 2022 to assist with the transition. Prior to joining Amazon, Paul was CFO of Hulu for six years.

15:22 EST Lockheed, Nanoracks team awarded $160M contract by NASA for Starlab design - Nanoracks, in collaboration with Voyager Space and Lockheed Martin, has been awarded a $160M contract by NASA to design its Starlab commercial space station as part of the agency's Commercial Low-Earth Orbit Development program. Starlab will enable NASA's initiative to stimulate the commercial space economy and provide science and crew capabilities prior to the retirement of the International Space Station, the companies said. The initial $160M award to Nanoracks is made via a funded Space Act Agreement through 2025. This initial NASA-provided funding will be supplemented with customer pre-buy opportunities and public-private partnerships. Fully owned by Nanoracks, Starlab is planned to reach initial operating capability in 2027, which ensures continuous human presence in LEO by U.S. entities. NASA will have the opportunity to purchase crew and payload services on Starlab through separate services contracts with Nanoracks, the companies stated. "Starlab is the confluence of Lockheed Martin's rich space expertise and history, Nanoracks' innovation, and Voyager's financial savvy. This team is equipped to aid NASA on its mission to expand access to LEO and to enable a transformative commercial space economy," said Lisa Callahan, Vice President and General Manager, Commercial Civil Space at Lockheed Martin.

15:12 EST Grizzly Research calls ReneSola 'fraudulent,' says most projects non-existent - In a recently publish report titled "We believe ReneSola is a Fraudulent Company; Most Projects Never Existed," Grizzly Research says that, "Our on the ground due diligence, filings review, and communications with local municipalities in Europe indicate that SOL has been vastly misrepresenting its project development pipeline. Most of SOL's projects are in Europe, but our research indicates that most of these projects seemingly do not exist. We were able to confirm this in several cases with the local government authorities, which leads us to believe that SOL might have fabricated projects to give the appearance of a better development pipeline and future economics. Worse yet, SOL continuously categorizes projects as 'late-stage,' and close to finalization, that our research shows to be either non-existent or delayed for years. Even the projects that we could identify were for the most part delayed by years and way behind company projections. We see similar issues with potentially fabricated and delayed projects in SOL's US business. [...] In summary, we believe SOL is a fraudulent company that drastically over-represents its project pipeline to access the US capital markets. SOL is led by what we believe to be a fraudulent team whose legal difficulties will ultimately also cause problems for SOL public shareholders. We see over 40% downside from current prices." In Thursday afternoon trading, shares of ReneSola have dropped over 10% to $5.89. Reference Link

14:14 EST Fast Acquisition lower as Fertitta tries to exit deal - Shares of Fast Acquisition Corp. are down nearly 5% after the special purpose acquisition company disclosed earlier that casino mogul and restaurateur Tilman Fertitta is trying to pull out of a deal to take his restaurant and casino empire public via a previously announced deal with the merger partner. Fertitta Entertainment, the parent company of Golden Nugget, and Fast Acquisition (FST), a special purpose acquisition company, previously announced on July 1 that they had entered into an amendment to their previously announced merger as Fertitta had agreed to contribute certain operating businesses not originally included as part of the business combination with Fast for no additional debt. However, the billionaire's general counsel sent a letter Dec. 1 to Fast Acquisition Corp. to state that Fertitta Entertainment would terminate the proposed transaction because it hadn't closed by an agreed-upon date, according to Bloomberg, citing a regulatory filing. In a letter in response, Fast Acquisition stated in part "Florida, or Fertitta Entertainment, "is not permitted to terminate the Merger Agreement pursuant to Section 9.01(a) because 'the right to terminate this Agreement under this Section 9.01(a) shall not be available to any party hereto whose action or failure to fulfill any obligation under this Agreement or the Separation Agreement shall have been the primary cause of the failure of the Closing to occur on or prior to such date'. Florida's actions and failures to fulfill its obligations under the Merger Agreement, including, without limitation, Florida's failure to deliver the financial statements required by Section 7.01(a) of the Merger Agreement until July 2021, despite being required to provide them no later than March 31, 2021, are unquestionably the primary cause of the failure of the Closing to occur by the Termination Date. Accordingly, the Purported Notice is invalid, unenforceable, of no legal force and effect and is hereby rejected. We hereby demand that Florida withdraw the Purported Notice immediately and take all necessary steps to consummate the transactions contemplated by the Merger Agreement forthwith... Florida's material breach has and will cause irreparable injury, and we intend to take all necessary steps to protect the SPAC and its investors. You are hereby placed on notice of breach and that should your breach not be immediately remedied, we intend to initiate litigation."

13:38 EST WEC Energy to increase dividend by 7.4% to 72.75c per share - The board of directors of WEC Energy announced that it is planning to raise the quarterly dividend on the company's common stock to 72.75c per share in the first quarter of 2022. This would represent an increase of 5c per share, or 7.4%. The directors expect to declare the new dividend at their regularly scheduled meeting in January. The dividend - which would be equivalent to an annual rate of $2.91 per share - would be payable March 1, 2022, to stockholders of record on Feb. 14, 2022. "The board's review today is consistent with our ongoing plan targeting a dividend payout ratio of 65 to 70 percent of earnings," said Gale Klappa, executive chairman.

13:07 EST Chanos says Wynn shares 'not cheap,' will not make money in 2022 - Jim Chanos, president and founder of Kynikos Associates, spoke earlier on CNBC.

13:02 EST AERC Stock trading resumes

12:57 EST AERC Stock trading halted, volatility trading pause

12:49 EST Jim Chanos discusses short position in DoorDash on CNBC - In an interview on CNBC, Jim Chanos, president and founder of Kynikos Associates, is discussing his short position in DoorDash (DASH), questioning if the company is not going to be profitable now, during a pandemic, then when will it be.

12:01 EST EU fines UBS, Barclays, RBS, HSBC, Credit Suisse EUR344M over forex probe - The European Commission has completed its cartel investigation into the Foreign Exchange spot trading market by imposing fines on five banks. The Commission has adopted a decision imposing a total fine of EUR261M on the four banks that decided to settle the case, namely UBS (UBS), Barclays (BCS), RBS (NWG) and HSBC (HSBC). The Commission has also fined Credit Suisse (CS) EUR83M under the ordinary procedure. Commissioner Margrethe Vestager, in charge of competition policy said: "Today we complete our sixth cartel investigation in the financial sector since 2013 and conclude the third leg of our investigation into the Foreign Exchange spot trading market. Our cartel decisions to fine UBS, Barclays, RBS, HSBC and Credit Suisse send a clear message that the Commission remains committed to ensure a sound and competitive financial sector that is essential for investment and growth. Foreign exchange spot trading activities are one of the largest financial markets in the world. The collusive behaviour of the five banks undermined the integrity of the financial sector at the expense of the European economy and consumers."

12:00 EST Elastic falls -13.3% - Elastic is down -13.3%, or -$18.48 to $120.65.

12:00 EST Kroger rises 12.4% - Kroger is up 12.4%, or $4.99 to $45.20.

12:00 EST Express rises 14.2% - Express is up 14.2%, or 48c to $3.86.

11:45 EST Bruker says FluoroType SARS-CoV-2 varID Q assay detects all variants - Bruker Corporation announced that its established CE-IVD marked FluoroType SARS-CoV-2 varID Q real-time multiplexed PCR assay reliably detects all SARS-CoV-2 variants, and in addition is expected to also provide a clear indication of Omicron, recently declared a 'variant of concern' by the WHO. FluoroType SARS-CoV-2 varID Q is a multiplexed CE-IVD marked PCR assay for the detection and quantification of all major SARS-CoV-2 variants, based on Bruker's proprietary LiquidArray technology. In addition, the assay simultaneously detects the S-gene mutations Del69-70 and N501Y, which are expected to be clear indications that the variant is Omicron. The new Omicron variant shares these mutations with the Alpha variant, but the Alpha variant is meanwhile of low epidemiological interest and only gets detected sporadically. Accordingly, by identifying Del69-70 and N501Y, the laboratory has an indication that the sample most probably is the SARS-CoV-2 Omicron variant. This can subsequently be confirmed by genomic sequencing, as is standard practice.

11:21 EST PLBY Group names Cardi B first ever creative director - PLBY Group announced via Twitter that Cardi Bi has become the company's first ever "Creative Director in Residence." Shares of PLBY Group jumped 3% to $36.07 following the news.

11:08 EST MoneyGram partners with urpay for cross-border payments from Saudi Arabia - MoneyGram International announced its partnership with urpay to enable cross-border money transfers. urpay is a digital wallet powered by neoleap, the Saudi-based financial global digital solutions company with a mission to create the most powerful yet simple fintech solutions. The partnership enables urpay to connect to the Company's API-driven infrastructure and global network to provide its millions of users the ability to send money around the world. The partnership is expected to be live for consumers in early 2022.

11:02 EST Brivo surpasses 1M Mobile access control credentials - Brivo, which recently entered into a definitive merger agreement with Crown PropTech Acquisitions, announced it has surpassed 1 million Brivo Mobile Pass mobile credentials worldwide. Mobile access credentials allow people to open doors, gates, and turnstiles using just their smartphone, which makes navigating spaces in offices, gyms, garages, schools and other places in the built world more convenient.

11:01 EST CF Acquisition Corp. VI soars after reaching deal to take Rumble public - Video platform Rumble and CF Acquisition Corp. VI (CFVI), a special purpose acquisition company sponsored by Cantor Fitzgerald, announced last night that they have entered into a definitive business combination agreement. After closing, which is expected in Q2 of 2022, the combined company will be called Rumble Inc. and expects to be publicly listed on Nasdaq. Shares will trade on Nasdaq under the symbol CFVI until the closing of the transaction. The transaction values Rumble at an initial enterprise value of $2.1B, with current Rumble shareholders having the ability to earn additional shares of the combined company if the stock reaches price hurdles of $15.00 and $17.50 per share. The transaction is expected to provide approximately $400M in proceeds to Rumble, including a fully committed PIPE of $100M at $10.00 per share and $300M of cash held in the trust account of CFVI. Upon the closing of the transaction, Chris Pavlovski, the Founder and Chief Executive Officer of Rumble, will retain voting control "to facilitate execution of Rumble's neutral mission on behalf of all stakeholders." The board of each of Rumble and CFVI have unanimously approved the transaction. The transaction will require the approval of the stockholders of each of CFVI and Rumble. Rumble stockholders have agreed to support the transaction. Shares of CF Acquisition Corp. VI are up 19% to $11.61 following the news. Rumble in an investor presentation highlighted that former President Donald Trump is among its top creators.

10:58 EST Bear Cave sees 'problems at Redwire' amid inability to file first 10-Q - The Bear Cave's Edwin Dorsey said in a recently published report titled "Problems at Redwire" that, "Redwire [RDW] went public through a SPAC merger at a $620 million valuation, but its seven underlying companies were acquired for approximately $150 million between February 2020 and June 2021. The premium appears to be a symptom of aggressive SPAC projections and spurious metrics. For example, the company's claimed $280 million backlog is largely "cancellable by customers for convenience" and Redwire's projection of 11x revenue growth over the next five years seems at odds with its inability to file its first 10-Q. In addition, a celebrity duo promoting an alleged partnership with Amazon [AMZN] appear less than credible." In Thursday morning trading, shares of Redwire have dropped over 4% to $7.78. Reference Link

10:35 EST Rallybio Holdings LLC trading halted, volatility trading pause

10:15 EST Foghorn Therapeutics trading resumes

10:10 EST Foghorn Therapeutics trading halted, volatility trading pause

10:04 EST Forma Therapeutics Holdings trading halted, volatility trading pause

10:01 EST BAE Systems awarded $316M contract from DLA - The Defense Logistics Agency has executed a $316M contract option for BAE Systems' advanced M-Code Global Positioning System modules, raising the contract funding to $641M. The modules provide dependable positioning, navigation, and timing for ground troops, vehicles, aircraft, and precision munitions. The contract will ensure the availability of Common GPS Modules for advanced military GPS receivers with anti-jamming and anti-spoofing capabilities that enable operation in contested environments. Under the contract option executed in November, BAE Systems will manufacture CGMs for future ground, airborne, and weapon GPS receivers for the U.S. Department of Defense and its allies. The award builds on a May 2021 $325M contract and enables BAE Systems to continue to meet domestic and international demand for Military GPS User Equipment Increment 1 M-Code modules in GPS receivers through the end of the decade.

10:00 EST Elastic falls -13.5% - Elastic is down -13.5%, or -$18.81 to $120.32.

10:00 EST Snowflake rises 9.6% - Snowflake is up 9.6%, or $29.99 to $340.99.

10:00 EST Express rises 16.3% - Express is up 16.3%, or 55c to $3.93.

09:51 EST Takeda Pharmaceutical announces U.S. commercial availability of Livtencity - Takeda Pharmaceutical announced the United States commercial availability of Livtencity, the first and only treatment for adults and pediatric patients with post-transplant cytomegalovirus infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet. Livtencity an orally bioavailable anti-CMV compound, became available for prescription on December 2, just over a week after the U.S. FDA approval which took place on November 23.

09:47 EST C3.ai falls -11.2% - C3.ai is down -11.2%, or -$3.78 to $30.05.

09:47 EST RLX Technology rises 9.5% - RLX Technology is up 9.5%, or 39c to $4.50.

09:47 EST Express rises 11.5% - Express is up 11.5%, or 39c to $3.77.

09:40 EST Katapult provides interim update on gross originations, lower than 2020 levels - Katapult Holdings provided an interim update on its quarter-to-date Gross Originations last night. The company booked Gross Originations from October 1, 2021, through November 30, 2021, of $40.4M. This compares to Gross Originations in the same period of 2020 and 2019 of $41.7M and $26.1M, respectively. Chief Executive Officer, Orlando Zayas, notes, "Our quarter-to-date Gross Originations were down 3.2% year-over-year, which reflects many of the same economic trends we saw in the 3rd quarter continuing into the 4th quarter. We look forward to seeing how December 2021 unfolds. We will provide more details in regard to Gross Originations and other key metrics when we report Fourth Quarter and Full Year 2021 results in 2022." In early trading, Katapult Holdings shares are down 36c, or 10%, to $3.30.

09:36 EST Kirkland's trading resumes

09:32 EST Redbox sees deploying digital video signage on 4,000 kiosks through partnership - Redbox announced it has deployed digital video signage on the top of over 2,000 kiosks across the US, with nearly 4,000 expected total installations. "Through a partnership with Velocity, A Managed Service Company, the new video screens give the company a powerful new way to partner with Hollywood studios to promote new release movies, its rapidly growing free streaming service, as well as provide advertising opportunities for national and hyper-local media campaigns that will be seen by millions of consumers in high traffic locations," Redbox stated. Direct ad sales for the new screens are handled by Redbox in partnership with Screenvision, and through connected programmatic exchanges, the company noted. "The addition of Velocity screens gives us a powerful new way to promote new release titles with our content partners including all major Hollywood studios, as well as provide brands and studios a uniquely customizable out of home campaign, while also promoting our free streaming service and Redbox Entertainment originals in high trafficked locations. We've already seen success with the screens we've tested to date, and we're excited to see this quickly scale and potentially grow to additional kiosks in the future," said Galen Smith, CEO, Redbox.

09:31 EST IMAC appoints Sandy Miller as chief of staff - IMAC Holdings announces a promotion and multiple new hires to accommodate the Company's rapid growth in both IMAC Regeneration Centers and The Back Space subsidiary. Sandy Miller, founding partner of IMAC's Ozzie Smith IMAC Regeneration Center in 2015, has been promoted to the position of Chief of Staff for IMAC. Ms. Miller has served as Vice President of Clinical Development for IMAC over the past three years. The Company has also hired Norleidy Hernandez as Human Resources Director. Ms. Hernandez joins IMAC from St. Charles Surgical Hospital where she served as Director of Human Resources. Additionally, Frank DeVito, III, has been hired as Director of Sales. Mr. DeVito comes to IMAC from Sage Settlements where he served as one of their leading sales consultants while working with thousands of attorneys nationwide.

09:28 EST Huron acquires Whiteboard Higher Education, terms undisclosed - Huron announced it has acquired Whiteboard Higher Education, a student enrollment advisory firm that helps colleges and universities with recruitment initiatives and financial aid strategies. The entire Whiteboard team will join Huron. Whiteboard will be included in Huron's Education operating segment. Terms of the acquisition, which closed, were not disclosed.

09:24 EST TEN, Ltd. announces charter extensions for Aframax tankers - TEN announced the charter extension for two aframax tankers for a combined period of 48 months to a major oil company. With these two transactions, the total number of long-term businesses secured over the last three months climb to 10 including ones with fixed and profit-sharing contracts. These 10 fixtures combined with the minimum charter proceeds of the LNG carrier and the Shuttle tanker to be delivered in the first and second quarter of 2022 respectively are expected to generate gross revenues of approximately $500 million.

09:23 EST Archer gets FAA airworthiness certificate for Maker demonstrator aircraft - Archer Aviation announced it has received a Special Airworthiness Certificate from the Federal Aviation Administration covering its Maker demonstrator aircraft. The Special Airworthiness Certificate authorizes Archer to begin flight testing its electric vertical takeoff and landing Maker aircraft. Having cleared this final threshold to begin off-ground operations, Archer remains on track to conduct its first hover flight test later this year. Archer has worked hard to maintain a collaborative and transparent relationship with the FAA through the Administration's Center for Emerging Concepts & Innovation and the Los Angeles Aircraft Certification Office throughout the certification process. This latest milestone follows Archer receiving its FAA G-1 Issue Paper: Certification Basis in September. "Earning our Special Airworthiness Certificate from the FAA marks a significant moment for our company as we take another leap ahead toward our goal of bringing eVTOL travel to the world," said Brett Adcock, Archer co-founder and co-CEO. "We're glad to share a commitment with the FAA to create urgently-needed air transportation solutions. We're grateful to have developed a strong relationship with their Center for Emerging Concepts & Innovation as we continue to work to ensure our eVTOL aircraft adheres to the highest standards of safety and compliance. In a year of exciting milestones for Archer, this moment serves as a key validator for the incredible work our team is doing to transform our vision for urban air mobility into a reality."

09:21 EST Aditx Therapeutics extends timeline to acquire AiPharma Global - Aditxt announced that it has entered into an amendment to its previously announced transaction agreement with AiPharma Global extending the outside date by which the parties have to execute a definitive agreement from November 30 to December 16, and to remove the $4M termination fee from the transaction agreement and associated credit agreement. In addition, the parties agreed to reduce AiPharma Global's borrowing capacity under the credit agreement from $8.5M to $8M and to require an aggregate cash payment of $500,000 to be made in one or more payments at the initial closing and/or secondary closing, as mutually agreed by the parties.

09:19 EST Seven Oaks Acquisition announces transfer of listing to NYSE - Seven Oaks Acquisition announced that it will voluntarily transfer the listing of its Class A common stock and public warrants from the Nasdaq Capital Market to the New York Stock Exchange in connection with, and upon the closing of, the previously announced business combination with Boxed. In connection with the Business Combination, all Seven Oaks units will be automatically separated and each of the then issued and outstanding shares of Class A common stock will convert automatically, on a one-for-one basis, into a share of common stock, par value $0.0001 per share, of the post-business combination company, to be renamed Boxed, Inc. The shares of common stock and public warrants of Boxed, Inc. are expected to begin trading under the stock symbol "BOXD" and "BOXD WS", respectively, on December 9, 2021. Seven Oaks' units, Class A common stock and public warrants will continue to trade on Nasdaq until the closing of the Business Combination. In compliance with Nasdaq's Listing Rules, Seven Oaks provided Nasdaq with notice of its intent to delist its Class A common stock and public warrants from Nasdaq after market close on December 8, 2021. The NYSE listing and Nasdaq delisting are subject to the closing of the Business Combination and fulfillment of all NYSE listing requirements.

09:17 EST Biofrontera issued notice of allowance for U.S. patent on illumination protocol - Biofrontera announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the U.S. patent application number 17/234,490, titled "Illumination for Photodynamic Therapy," that covers an innovative, pain-reducing illumination protocol for photodynamic therapy. The patent application claims a method for photodynamic therapy in which a dynamic and innovative illumination protocol is implemented. This protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to specifically modulate and reduce pain perception to the patient. The new illumination protocol aims at combining the high efficacy of Ameluz with the flexibility of BF-RhodoLED to modulate light for pain reduction to ultimately become a new standard-of-care in PDT. Implementation of the protocol to Biofrontera's medical devices requires a software installation and can be rolled-out to both the BF-RhodoLED and BF-RhodoLED XL lamps. To include this illumination protocol in the U.S. prescribing information, Biofrontera Group, in accordance with pipeline development under the license and supply agreement between Biofrontera Inc. and Biofrontera AG, will start a Phase 3 trial for the treatment of actinic keratoses on the face and scalp with 3 tubes of Ameluz and the RhodoLED XL lamp involving the new protocol in 2022. Within the scope of the LSA between Biofrontera Inc. and Biofrontera AG and its Germany-based subsidiaries, Biofrontera Inc. holds the exclusive rights to market and sell Ameluz and the PDT-lamps BF-RhodoLED as well as the advanced BF-RhodoLED XL in the United States. Under the LSA, the Licensor holds the patents for the licensed products.

09:14 EST American Battery announces sampling results at 305 lode mining claims - American Battery Technology announced initial sampling results at its recently secured 305 lode mining claims located on land administered by the Bureau of Land Management in Little Smokey Valley near Tonopah, Nev. The ABTC field team analyzed 29 new surface sample locations, along with existing samples previously collected by other parties, and the resulting data demonstrated grades of anomalous reported lithium present from 260 ppm to 1,530 ppm in the project area. Samples with values of 300 ppm and up are typically considered very prospective in nature. The historic samples were analyzed by ALS Analytical Lab in Reno Nev., and the samples collected by ABTC were assayed at the American Assay Laboratory in Reno, Nev. As a result of the initial surface sample characterizations, ABTC has submitted a Notice of Operation permit and Reclamation Bonding to the Bureau of Land Management Tonopah Field Office for subsurface samplings of these claims. Exploratory subsurface sampling is the next sequential step in moving towards developing this resource where the sample results will be used to define the extent of the deposit in footprint, depth, and the grades of the lithium. Preliminary evaluation of historical sampling and characterization efforts have indicated that the composition and structure of the resources on these claims could be representative of resources identified on nearby claims in the same region. In April 2020, American Lithium published a resource assessment of their 7,500-acre TLC project, which directly borders these ABTC secured claims, which stated a Measured and Indicated resource of 5.37 million tonnes of lithium carbonate equivalent, with an additional 1.76 million tonnes inferred. Over the past two years, ABTC has been designing and optimizing its internally-developed processing train for the manufacturing of battery cathode grade lithium hydroxide from these Nevada-based sedimentary claystone resources. The majority of these development efforts to date have been performed with sedimentary claystone resource samples provided by partner companies in the Tonopah, Nev. region. While ABTC will continue to work with these partners to refine, test, and validate its internally developed technologies for potential commercialization at these resource sites, ABTC is also evaluating the performance of its lithium extraction and manufacturing technologies directly on its own lithium-bearing resource.

09:10 EST Amazon announces Rivian selects AWS as 'preferred cloud provider' - Amazon Web Services or AWS announced that electric vehicle maker Rivian (RIVN) has selected AWS as its preferred cloud provider, deepening the companies' existing relationship. Across its enterprise, the automaker applies AWS capabilities in analytics, compute, containers, and machine learning to help streamline its business and improve the performance of its customers' electric vehicles-for battery range, driving experience, and owner experience-while simultaneously innovating the technological foundations for customers' electric vehicle fleet management and more efficient vehicle charging. Rivian applies these innovations across its vehicle lines, including custom-built electric delivery vans for Amazon.com. Through these developments, Rivian aims to accelerate the consumer and commercial shift to electric vehicles and make transportation cleaner and more sustainable in accordance with its goals under The Climate Pledge.

09:07 EST Duck Creek Technologies OnDemand selected by SECURA Insurance - Duck Creek Technologies announced that SECURA Insurance, a North American property and casualty insurance carrier, has selected Duck Creek Rating, Policy, Claims, and Insights to streamline its P&C business and power the next generation of its Specialty Lines operations. SECURA has chosen to implement its new digital solutions via Duck Creek OnDemand, the provider's SaaS solution for the P&C insurance industry. OnDemand is Duck Creek's end-to-end SaaS solution, providing the services, support, and computing resources needed to help carriers move faster and more efficiently. "This commitment represents a major digital transformation move for SECURA and is yet another sign that insurers worldwide are adopting SaaS solutions for the most critical functions of their organizations," said Matt Foster, COO of Duck Creek Technologies. "Duck Creek OnDemand will let SECURA focus on its customers, agents, and products, while we provide application services and upgrades behind the scenes. We are thrilled to expand our relationship with SECURA and look forward to continuing to help them grow and succeed."

09:06 EST Verizon offering 5G Home, Business Internet in Dayton, OH, Jacksonville, FL - Verizon is offering more customers more super fast 5G internet for their homes and businesses. Customers in parts of Dayton, OH and Jacksonville, FL can now sign up for 5G Home Internet or 5G Business Internet, depending on their needs. Both services are ideal for anyone who wants super fast connectivity to stream, game or work flexibly.

09:05 EST Exco Technologies publishes first sustainability report - Exco Technologies announced it has published its inaugural Sustainability Report. This milestone reflects our growing focus on our Environmental, Social and Governance priorities, and facilitates a deepening dialogue with our stakeholders about these issues. As discussed in the report, our ESG strategic priorities are built upon our core values and are designed to ensure that Exco achieves its vision - to be the benchmark for innovation, quality and efficiency in the industries we serve. Looking at our business strategies through the ESG lens is critical to our success in a world where all of our stakeholders are concerned with issues of environmental and social sustainability. In addition to evolving marketplace dynamics, the report describes our initiatives to protect the environment, support our people, give back to society, and ensure robust corporate governance structures.

09:04 EST EnWave sells second 10 kW REV machine to Dairy Concepts IRL - EnWave announced that Dairy Concepts IRL has signed an Equipment Purchase Agreement to acquire its second 10kW Radiant Energy Vacuum dehydration machine for commercial use at Moorepark Technology Limited's facility in Cork, Ireland. DCI signed a royalty-bearing commercial license agreement with EnWave in September 2020, granting it processing rights for a portfolio of natural, sweet and savoury, shelf-stable, hand-held dairy snacks. To facilitate initial REV processing, DCI forged a commercial relationship with MTL. MTL provides commercial pilot plant and research services for food industry customers. DCI and MTL have collaborated to combine leading technology with food innovation strategy to launch new and exciting dairy-based products to the market in Europe. MTL previously purchased a 10kW REV machine from EnWave in September 2019 and this machine has been used commercially by DCI since September 2020. In March 2021, EnWave sold a second 10kW REV unit to DCI to expand its manufacturing capacity at MTL, and the addition of a third 10kW REV machine will continue to increase production capacity at the MTL facility. DCI will use all three of the existing REV machines at MTL for the production of CheeseOs and its premium specialty cheese brand Moorepark.

09:03 EST Progress Software announces Milwaukee County, Wisconsin implement MOVEit MFT - Progress announced that Milwaukee County, Wisconsin implemented Progress MOVEit secure managed file transfer, MFT, to centralize dozens of disparate file transfer systems and serve its many constituencies more efficiently. "Moving files securely in and between local, state, federal government departments and agencies is business-critical as these files usually contain extremely sensitive citizen data," said John Ainsworth, SVP, Core Products, Progress. "With MOVEit, Milwaukee County can securely configure, deploy, and manage data and information exchange from a central location, while tracking and guaranteeing their delivery." After a thorough evaluation of multiple MFT software providers, Milwaukee County chose Progress MOVEit because it gave them the ability to quickly onboard and integrate a wide variety of disparate data systems and processes, minimizing complexity and allowing for more centralized management. Looking ahead, the team expects to triple their use of MOVEit managed file transfer in the next year and they plan to explore the advanced workflow automation capabilities of Progress MOVEit Automation and Progress MOVEit Transfer for secure collaboration, adding more modules as the need arises.

09:01 EST Sonoco Products to increase tube, core price by 10% in EMEA regions - Sonoco-Alcore S.a.r.l. announced that due to continued inflationary pressure on the business, it will raise prices by 10% on all tube and core grades sold in the Company's EMEA regions. The increase will be effective for all shipments made on or after the 13th December 2021. "We continue to experience further cost increases in all sectors of our operations and supply chain. Even with a strong focus on implementing productivity initiatives, they are not enough to offset inflationary pressures from energy, packaging, transportation, adhesives and raw materials. As such, we are forced to pass on cost increases to the market," said Karsten Kemmerling, Division VP - Sales & Marketing EMEA.

08:56 EST BNY Mellon's Pershing to acquire Optimal Asset Management, terms not disclosed - BNY Mellon's Pershing announced it has entered into a definitive agreement to acquire Optimal Asset Management, a direct indexing solutions provider. Optimal Asset Management's patented, cutting-edge software provides customizable direct indexing solutions to investors seeking personalized portfolios that are aligned to their values. The acquisition will form part of the new Pershing X offering - a recently launched business unit within Pershing that will design and build innovative solutions for the advisory industry.

08:49 EST AgriFORCE signs contract with Humboldt to deploy grow house facility - AgriFORCE Growing Systems has signed a definitive contract with Humboldt Bliss. The contract is for the deployment of the AgriFORCE foundational IP - which includes a facility design, production and operation technologies and methods, and an automated growing system for the cultivation and sale of high value medical and agricultural products into the Caribbean and global pharmaceutical and agricultural markets. Under the terms of the contract, AgriFORCE is responsible for constructing its proprietary facility and providing the full Standard Operating Procedures of the AgriFORCE Grow House and Humboldt is responsible for securing the project's land as well as operating the facility. Upon production, Humboldt has committed to remit an IP licensing, management services and equipment leasing fee to AgriFORCE for up to 14,300 pounds of high value medical and agricultural crops per year. The contract will be backed by a rolling $5M performance bond maintained by Humboldt. AgriFORCE CEO Ingo Mueller stated: "Finalizing this agreement is exciting, and we are looking forward to deploying our Grow House facility in Barbados. We believe that this facility may generate over $12 million of EBITDA per year based on current contracts with the potential to further expand production based upon up to a further 50% of available installed capacity. Moreover, we have a robust sales pipeline and we believe this is only the first of several agreements to roll out our Grow House facilities in the coming months."

08:46 EST Norfolk Southern CEO James Squires to retire in 2022, Alan Shaw to succeed - Norfolk Southern announced that Chairman and CEO James Squires plans to retire on May 1, 2022, at which time Executive Vice President and Chief Marketing Officer Alan Shaw will become CEO. As part of the company's planned succession process, the board of directors has elected Shaw to the role of president, effective immediately. The company's executive leadership team now reports to Shaw. Squires and Shaw will continue to work closely together over the next five months to complete a smooth transition.

08:46 EST Codiak announces new preclinical data from exoVACC platform - Codiak BioSciences announced new preclinical data from its exoVACC exosome-based vaccine platform. The study reported the generation of a neutralizing antibody response that showed evidence of activity against multiple SARS-CoV-2 variants. In addition, the ability of exoVACC to generate antigen-specific T cell responses against structurally conserved regions of multiple coronavirus variants provides evidence of a broad immune response to the candidate. The results are being presented today at the World Vaccine & Immunotherapy Congress, WVIC, 2021 in San Diego. "Our goal is to advance a pancoronavirus vaccine candidate that has the potential to be broadly protective against infection with SARS-CoV-2, CoV-2 variants and other novel beta coronavirus family members. We believe Codiak's exosome engineering platform will allow us to engineer antigens to elicit T cell and antibody responses against this virus family to generate immunity," said Douglas Williams, Ph.D., President and Chief Executive Officer of Codiak. Codiak's vaccine system platform leverages engineered exosomes to precisely control antigen display on the surface or in the lumen, in order to deliver antigens, adjuvants and immunomodulators simultaneously and selectively to antigen presenting cells to maximize immune response. The data presented at WVIC show that an exosome carrying the SARS-CoV-2 RBD induced an antibody response in mice that was 100-fold greater than recombinant, or "free" RBD, highlighting the advantage of the exosome surface display. When a STING agonist was added to the exosome to function as an adjuvant, the antibody response observed in preclinical studies was further enhanced and comparable to that of human subjects vaccinated twice with an mRNA vaccine against SARS-CoV-2. Additionally, Codiak, in collaboration with Gaurav Gahia, M.D., principal investigator at the Ragon Institute, identified multiple T cell epitopes that are highly conserved and invariant across all Beta coronaviruses including the known SARS-CoV-2 variants and the recently identified Omicron variant.

08:44 EST National Retail Solutions joins Geopath to enhance advertising capabilities - National Retail Solutions, a subsidiary of IDT Corporation, announced that its NRS Digital Media division, which operates NRS' rapidly expanding digital out-of-home, DOOH place-based advertising network, has joined Geopath, a non-profit provider of industry-standard out-of-home, OOH, advertising metrics. The integration of Geopath's audience measurement, consumer insights, and market research equips NRS Digital Media with tools to enhance the reach of its DOOH advertising platform. "Advertisers expect access to robust audience data to validate media activations and measure returns," said Eli Korn, COO of NRS. "Our membership in Geopath provides brands and media planners with new and more granular insights into the unique audiences found in NRS stores to inform more effective media placement decisions."

08:41 EST Berkeley Lights debuts in France as MImAbs acquires Beacon system - Berkeley Lights and MImAbs announced the acquisition of the Berkeley Lights Beacon system via a TechAccess subscription to help further its mission of helping its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases. This marks the first Beacon platform to be used in France. The Beacon platform will replace MImAbs' hybridoma system. "We are looking forward to supporting MImAbs as they transition away from hybridoma technology to the most advanced antibody discovery platform on the market today," said Berkeley Lights Chief Executive Officer, Eric Hobbs, Ph.D. "Investigators need faster and better discovery technologies to more rapidly and effectively serve patients and Berkeley Lights can help meet that need."

08:39 EST Albireo Pharma appoints Constantine Chinoporos as CBO - Albireo Pharma announced the appointment of Constantine Chinoporos as Chief Business Officer and a member of the Albireo Enterprise Leadership Team. Mr. Chinoporos was most recently at Boston Pharmaceuticals where he was the Chief Business Officer responsible for all business development, new product planning operations and in-licensing of 20 programs over his tenure.

08:39 EST Yield10 Bioscience to present on advances using CRISPR genome editing - Yield10 Bioscience announced that its Chief Science Officer Dr. Kristi Snell will present during the Canola Week 2021 Conference taking place in virtual format November 30 through December 2, 2021. Dr. Snell will make a pre-recorded virtual presentation on December 2, 2021 as part of Canola Innovation Day. Her presentation, entitled "Genome editing to increase seed oil in Camelina," will describe the use of CRISPR genome editing to increase seed oil content in Camelina as well as the use of the GRAIN platform to identify novel editing targets for oilseed crops. Yield10 researchers have identified and are currently developing novel traits to increase seed oil content in oilseed crops. Yield10 plans further work with these novel oil content traits including the evaluation of trait combinations. "Demand for oil feedstock for production of renewable diesel in the U.S. and Canada is expected to rise significantly over the next five years," said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. "We believe that our GRAIN platform has enabled us to identify valuable new traits to meaningfully increase oil content in oil seed crops to meet the emerging growth in demand for oil in biofuel applications. Our work in Camelina has the potential to transform the crop into a high revenue, high yield, and low carbon index crop for securing acreage to produce renewable diesel feedstock."

08:36 EST Omnicell to acquire ReCept Holdings for $100M, sees accretion in 1Q23 - Omnicell announced it has entered into a definitive agreement with ReCept Holdings a provider of specialty pharmacy management services for health systems, clinics, and physician groups, to acquire its business for total aggregate cash consideration of $100M subject to customary adjustments. The acquisition will broaden Omnicell's portfolio of capabilities and services to address the significant need to improve access to and care coordination for complex medications. Studies have shown that specialty medications represent over 50 percent of the country's total spending on retail, mail-order, and provider-administered drugs.1 Used for treatment of complex conditions, these medications often require intensive patient management and specialized workflows for dispensing and care coordination. Specialty pharmacies serve as the connection between patients, prescribing physicians, and payors to ensure streamlined access and adherence to these specialty drugs, helping to maintain continuity of care throughout the process, and are expected to improve margin and profitability. As an Advanced Services organization, ReCept provides implementation and managed services for health systems and other provider organizations to optimize their specialty pharmacy programs and the related pharmaceutical aspects of patient care. Under the terms of the agreement, Omnicell will pay total aggregate cash consideration of $100M, subject to customary adjustments, at closing as provided for in the agreement and plan of merger. The transaction, which is expected to close by the end of the year, is subject to Hart-Scott-Rodino clearance and the satisfaction of other customary closing conditions. The ReCept business that is being acquired recorded approximately $24M of total revenue for the 12 months ended September 30. Omnicell will use cash available on its balance sheet to fund the transaction. Upon closing, the transaction is expected to be accretive to Omnicell's non-GAAP EBITDA beginning in the first quarter of 2023.

08:36 EST Medallion Financial announces sale of NASCAR race team investment - Medallion Financial announced that it has closed on the exit of its investment in its NASCAR race team - Richard Petty Motorsports - to Warp Speed. The Company received $19.1M of gross proceeds in full settlement of all debt and equity securities it held. The transaction results in a complete divestiture of RPAC by the Company, removes $26M of intangible assets from the Company's balance sheet and increases the Company's tangible book value by over $1 per share. Executive Commentary - Andrew Murstein, President and Chief Operating Officer, "Richard Petty is one of the most iconic names in professional sports. We are extremely proud of what we accomplished during our tenure with Richard Petty Motorsports, including winning numerous races, bringing greater diversity to the motorsports industry, and helping position RPAC for long-term success. We look forward to passing the baton to the next steward of this great legacy in this great sport."

08:35 EST Dyne announces submission of IND application to start trial of DYNE-251 - Dyne Therapeutics announced the submission of an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy, DMD, amenable to skipping exon 51. "In a little over three years, we've been able to move Dyne from concept to clinic because we are steadfast in our commitment to bring potentially transformational therapies to people living with serious muscle diseases," said Joshua Brumm, president and chief executive officer of Dyne. "The IND submission for DYNE-251 represents a significant milestone. I am so proud of what our team has accomplished, and I want to thank all Dynamos and our partners in the rare muscle disease community. We look forward to an exciting 2022 as we expect to submit an IND for DM1 in the first quarter, begin dosing patients in clinical trials for both our DMD and DM1 programs by mid-year, and submit an IND for our FSHD program in the second half."

08:33 EST Iteris awarded $1.4M FDOT task order - Iteris announced that it has been awarded a $1.4M task order from Metric Engineering to support the Florida Department of Transportation, or FDOT, for a regional smart mobility, safety and sustainability program, representing continued demand for Iteris' specialized consulting services in Florida, a key geographic market.

08:33 EST Bravour awarded EUR95M on base IDIQ by NATO - Bravour Leistungen was awarded a EUR95M single-award, indefinite delivery/indefinite quantity contract by the North Atlantic Treaty Organization Support and Procurement Agency. The three-year award may be extended by two option years. Under this contract, Bravour will provide services for U.S. military vehicles at facilities throughout Europe. In addition to vehicle services supporting NATO efforts, Bravour delivers solutions for various NSPA initiatives across Europe, including the management of hazardous material management system operations, ammunition X-ray operations and quality assurance and surveillance inspection support.

08:31 EST Joann, Singer announce join venture to launch sewing, craft products - JOANN and SINGER announced the formation of a joint venture that will launch products and services with patented technology that "literally reinvents the sewing pattern process, making them easier to use and accessible anywhere and at any time," the company said. These new technologies have been developed in conjunction with leading artificial intelligence and sewing technology partners as well as one of the world's leading product design firms. The joint venture will launch in 2022. The products and related services will be sold initially domestically through various channels, including a direct-to-consumer model, at all JOANN store locations, and through Singer's dealer network that extends throughout the United States and to nearly 180 other countries. The joint venture will be led by Stacey Weller, a veteran in the sewing and craft industry, and will be based at SVP Worldwide's headquarters outside of Nashville, Tennessee. "For more than a century, crafters and sewers have largely endured the same arduous process that their ancestors used to make apparel, quilts, craft projects, decor and more," said Wade Miquelon, President & CEO of JOANN. "The technologies we are developing turn the most painful part of this journey into the most fun. Imagine instant access to thousands of established patterns, plus literally millions of potential self-designed variations, which can then be projected and cut quickly and accurately. JOANN is thrilled to partner with Singer, another legendary leader in the consumer creative space, to help transform the industry and make it easier and more enjoyable for crafters and sewists to bring their visions to life."

08:30 EST Alpine IQ announces partnership with High Tide - Alpine IQ announced its partnership with High Tide. High Tide tapped Alpine IQ to power its loyalty program, leveraging the company's robust suite of tools to engage with customers, drive increased satisfaction, and ultimately, repeat visits. With legal cannabis sales in Canada expected to rise 68% to $5.4B in 2022, and with more consumers turning to online ordering, Alpine IQ empowers dispensaries to meet the demands of today's consumer.

08:28 EST InterCure announces partnership with Cookies - InterCure announced its international expansion into Europe through a partnership with iconic cannabis brand Cookies. The parties entered into a multi-year agreement under which InterCure expects to establish Cookies stores and medical cannabis pharmacies in Austria and the United Kingdom in early 2022, subject to local regulations. InterCure, a Cookies' international partner, is already cultivating, manufacturing and distributing Cookies' GMP standard, branded products through its Cookies' national medical cannabis pharmacy chain in Israel. InterCure will leverage its licensed international supply chain to serve the growing communities of medical cannabis patients in Europe.

08:27 EST Orca Energy Group sees 2022 capex $50M - Orca Energy Group announces an operations update and guidance for 2022. Well Workover Program: Following acceptance testing, the Exalo S.A drilling rig is onsite Songo Songo Island and remediation work has commenced on SS-3, the first of a planned three well onshore workover program. The $20.5 million program includes the reactivation/recompletion of the SS-3 and SS-4 wells to access incremental gas reserves in the SS east pool and provide additional gas deliverability to the SS gas plant. Together with the SS-3 and SS-4 wells, the SS-10 well, which remains in production, will be worked over and completed with a new corrosion resistant chrome alloy production tubing string in accordance with the Company's ongoing corrosion monitoring and infrastructure integrity management system. With the completion of the workover program in Q1 2022, all the producing gas wells in the SS gas field will be equipped with the corrosion resistant tubing strings to ensure continued reliable gas production to the Tanzanian power sector and industrial customers in the Dar es Saleem region. Inlet Compression Project: Initiated in 2019, the $41.5 million inlet compression project is nearing completion, with a potential startup ahead of the contractual April 2022 target, following tie in to the SS gas plant and commissioning planned for early 2022. The inlet compression will allow production volumes to be sustained through the Songas Limited infrastructure at approximately 102 million standard cubic feet per day in the near term. Subject to demand volumes, natural reservoir pressure declines and the associated well performance, the $63 million invested in workovers and inlet compression facilities at the Songas infrastructure when combined with gas supplied to the National Natural Gas Infrastructure will provide the opportunity to initially increase total production capacity from the SS gas field in early 2022. The Company has approved a capital expenditure program of $50 million for 2022, subject to requisite government approvals, equipment and contractor availability. The 2022 program includes $20 million for a 200 km2 3D seismic program over the SS development license, $11.5 million to expand the Company's existing downstream gas distribution system, approximately $7 million for ongoing maintenance and facilities projects and an estimated $11.5 million of expenditures in 2022 associated with the current work over program and inlet compression project. If approved by the Government of Tanzania, the $20 million 3D seismic program will acquire approximately 200 square kilometers of full fold data comprised of marine, near shore transition and land based seismic to properly image the existing SS gas field and the additional contingent/prospective resources in the SS license acreage. The existing seismic data base is a coarse grid of 2D seismic lines of various vintages ranging from 1978 to 2009 which are insufficient to image and resolve the emerging compartmentalization and complexity of the SS gas field identified through annual pressure surveys and pressure transient analysis. The 3D seismic program is required to de-risk both the future development drilling in the SS gas field and potential exploration drilling of prospective resources prior to the SS license expiring in October 2026. Based on historical pressure declines, current reservoir simulation modeling and internal gas demand forecasts, additional drilling will be required to ensure adequate supplies of natural gas in the near term and beyond 2026. Subject to regulatory approvals and contractor availability, the Company is targeting a mid-year commencement of the 3D seismic program to align with seasonal meteorological conditions. The $11.5 million budgeted for the Company's subsidiary, PanAfrican Energy Tanzania Limited's downstream distribution system includes expansion of the Dar es Salaam ring-main pipeline distribution and further expansion of the compressed natural gas virtual pipeline system to supply natural gas to potential industrial customers and expand the use of CNG in the transportation sector. Expansion of the CNG VPL system is subject to commercial negotiations and government approvals. The expansion of PAET's VPL and CNG business will enable the extension of gas supplies, accelerate industrial expansion outside of Dar es Salaam, and more widely avail gas to Mwananchi. Moreover, it will further displace imported expensive liquid fuels with a higher carbon content, assisting Tanzania in reaching its sustainable development goals, including reducing inequalities, promoting decent work and economic growth, and meaningful climate action. Based on historical gas demand and on internal forecasts, Orca forecasts average gross conventional natural gas production of 60 - 66 MMcfd, which will be classified as "Additional Gas" under the terms of the PSA representing a potential 7% increase year-on-year over estimated gross conventional natural gas production of ~ 58 MMcfd in 2021. When combined with an estimated ~ 40 MMcfd of conventional natural gas production, which will be classified as "Protected Gas" under the terms of the PSA, the total average gross conventional natural gas production from the SS gas field is estimated to be ~ 100- 106 MMcfd for 2022. Orca continues to benefit from a robust balance sheet, with cash and cash equivalents of ~ $71.8 million and long-term debt of ~ $44.6 million as at November 29, 2021. The Company anticipates that its planned capital program will be funded from existing working capital and forecast cashflow. The Company has signed several new gas sales agreements in 2021 across numerous industrial sectors, and is in discussion/negotiations with a number of potential new industrial customers looking to convert from expensive imported liquid fuels to domestic natural gas. On November 19, 2021, Orca declared a quarterly cash dividend of $0.10 per share on each of its Class A common voting shares and Class B subordinate voting shares. The dividend will be paid on January 14, 2022 and is expected to be of a similar financial amount to the previous quarterly dividend, with an average yield in 2021 of ~8%. The Company continues to monitor its financial position and will look to balance both investing in production growth at SS, for the benefit of the country's expanding economy, while also returning value to shareholders as appropriate. In accordance with the Company's dividend policy, Orca anticipates maintaining its quarterly dividend.

08:24 EST 17 Education & Technology appoints Minghui Wu to board - 17 Education & Technology Group announced that Minghui Wu has been appointed as a new independent director to the Company's board of directors, effective on December 2, 2021. After the changes, the Board will consist of seven directors, three of whom are independent directors. Wu is chairman and CEO of MiningLamp Technology Co, an artificial intelligence and data analytics company he founded in 2014 that helps public service organizations and businesses with digital transformation. Concurrent with the appointment of Wu, the Board has approved to further update the composition of the Board's committees in furtherance of good corporate governance. The Board's three committees will be fully independent with composition are as follows: Audit Committee: Chair: Bing Yuan; Members: Jiawei Gan, Minghui Wu. Nominating and Corporate Governance Committee; Chair: Jiawei Gan, Members: Bing Yuan, Minghui Wu. Compensation Committee: Chair: Minghui Wu, Members: Bing Yuan, Jiawei Gan

08:21 EST Delcath Systems announces phase 3 FOCUS study results for Hepzato - Delcath Systems announced positive results from the phase 3 FOCUS study. The FOCUS study's intent-to-treat, ITT, population was comprised of a total of 102 subjects, across various lines of therapy. Of the ITT group, 91 evaluable patients were administered at least one study treatment. Treatment with HEPZATO in the ITT analysis resulted in an objective-response-rate, ORR, of 31.4%, including 6.9% of patients with a complete response, CR. Median duration of response was 14 months, with over half of responders continuing to be monitored for progression events. Disease control rate, DCR, was 65.7%. On the primary ORR endpoint, the lower bound 95% Confidence Interval, CI, of 22.55% exceeded the FOCUS trial's prespecified 8.3% upper bound 95% CI threshold for success. This threshold was derived from a meta-analysis of sixteen checkpoint inhibitor publications documenting the treatment of 476 metastatic ocular melanoma patients. Among patients who received at least one study treatment, patients in the HEPZATO arm had statistically significant improvements over BAC in the following prespecified endpoints: ORR of 35.2% versus 12.5% for the BAC arm; Disease Control Rate of 73.6% versus 37.5% for patients in the BAC arm; and Median Progression Free Survival of 9.03 months versus 3.12 months for the BAC arm. As of this analysis, survival at 12-months in the evaluable patients was 75% in the HEPZATO arm versus 47% for BAC. Delcath will provide future overall survival analysis updates, as patient follow-up continues, and the Kaplan-Meier analysis matures. In the HEPZATO safety population, the most commonly reported treatment-emergent serious adverse events were anemia, thrombocytopenia and neutropenia, which were well-manageable. There were no treatment-related deaths in the trial.

08:20 EST Freshworks helps 7-Eleven improve omnichannel customer experience - Freshworks has helped leading global convenience store 7-Eleven create a more delightful digital experience for its customers and franchise partners in the Philippines. Using Freshdesk(R) and Freshdesk Contact Center, 7-Eleven automates and more quickly resolves queries to deliver the same in-store conveniences to their regular customers and online shoppers. Philippines Seven Corp has been the pioneer of 24-hour convenience stores in the country with over 3000 branches. Since launching in the Philippines in 1982, 7-Eleven has been fueled by a desire to bring convenience like never before to its customers. They chose Freshdesk in 2019 to extend this philosophy to its omnichannel customer support. With Freshworks, 7-Eleven was able to consolidate all of its customer support into one platform. The customer care team that handles the general store and payment queries and the CLiQQ group that handles queries related to the 7-Eleven Loyalty program now use Freshdesk. As a result, 7-Eleven now has a unified control center for its customer and partner experiences in the Philippines.

08:18 EST Exela Technologies announces extension of early tender time, expiration time - Exela Technologies announced that it has further extended the early tender time and the expiration time, in each case, from 5:00 p.m., New York City time, on December 1, 2021 until 5:00 p.m., New York City time, on December 3, 2021 with respect to the previously announced exchange offer by certain of its subsidiaries for the Issuers' outstanding 10.000% First-Priority Senior Secured Notes due 2023 and a solicitation of consents to proposed amendments with respect to the indenture governing the Old Notes as described in the Offering Memorandum. The extension was implemented to accommodate additional tenders after the expiration of the Original Tender Time by certain holders of Old Notes. As of the Original Tender Time, approximately $893.5 million, or 95.5%, of outstanding Old Notes were validly tendered for exchange pursuant to the Exchange Offer. The deadline to validly withdraw tenders of the Old Notes has passed and has not been extended. As of the Original Tender Time, the Issuers have received the requisite consents to the proposed amendments to the indenture governing the Old Notes, including to eliminate substantially all of the restrictive covenants contained in the Old Notes Indenture and the Old Notes, eliminate certain events of default, modify covenants regarding mergers and consolidations and modify or eliminate certain other provisions, including certain provisions relating to future guarantors and defeasance, contained in the Old Notes Indenture and the Old Notes. In addition, all of the collateral securing the Old Notes would be released upon consummation of the Exchange Offer. Old Notes validly tendered and not validly withdrawn at or prior to the Extended Tender Time will still be eligible to receive $900 in cash per $1,000 principal amount of the Old Notes, up to the maximum amount of $225 million in cash. As the cash offer is already oversubscribed, Old Notes validly tendered and not validly withdrawn at or prior to the Extended Tender Time will be accepted for cash on a pro rata basis. The remainder of Old Notes validly tendered and not validly withdrawn at or prior to the Extended Tender Time and not accepted for cash will be exchanged into the Issuers' 11.500% First-Priority Senior Secured Notes due 2026on the basis of $1,000 principal amount of the New Notes for each $1,000 principal amount of outstanding Old Notes. The Company expects settlement for the Exchange Offer to occur promptly after the Extended Tender Time. The Exchange Offer and the Consent Solicitation are being made upon the terms and conditions set forth in the confidential offering memorandum and consent solicitation statement, dated October 27, 2021 as supplemented by Supplement No. 1, dated November 19, 2021 as further supplemented by Supplement No. 2, dated November 26, 2021, and the press releases, dated November 10, 2021, November 19, 2021 and November 26, 2021, relating to the Old Notes. Capitalized terms used but not defined in this press release have the respective meanings ascribed to such terms in the Offering Memorandum.

08:15 EST Olink participates in proteomics study for heart failure treatment options - Olink Holding announced that its project with Boehringer Ingelheim, assessing the potential utility of protein biomarkers in the empagliflozin EMPEROR studies, recently entered the data analysis phase. Empagliflozin, approved in the US under the tradename JARDIANCE, is a product used to lower blood sugar in patients with type 2 diabetes, and also to reduce the risk of cardiovascular death in those with type 2 diabetes who have known cardiovascular disease. JARDIANCE is also under Priority Review at the US FDA as a potential new treatment to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure independent of left ventricular ejection fraction. The sNDA is based on results from the EMPEROR-Preserved Phase 3 trial, in which Jardiance was associated with a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with LVEF over 40% compared with placebo. Results were independent of ejection fraction or diabetes status. Olink believes this effort represents one of the largest proteomics analysis directed at an approved drug, and that it could provide a better understanding of human biology, drug pharmacodynamic effects, and may also identify biomarkers allowing for better patient stratification. The analysis is being led by Boehringer Ingelheim and Prof Faiez Zannad, one of the principal investigators of the EMPEROR studies, and is being conducted with the Olink Explore platform. The analyses will collect and measure circulating protein biomarkers in 1,500 blood samples from EMPEROR-Reduced and 1,500 blood samples from EMPEROR-Preserved in an effort to reveal a potential mode of action and the underlying biology in patients with heart failure. Sample collection, and proteomic analyses and data delivery occurred during the third quarter of 2021, with analyses now ongoing. It is expected that the results of these analyses will be communicated by Boehringer Ingelheim at a later date.

08:12 EST Merus announces poster presentation on MCLA-145 at ESMO-IO - Merus (MRUS) announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at the ESMO Immuno-Oncology, ESMO-IO, Congress 2021 being held December 8-11, 2021 in Geneva, Switzerland. Presentation Details: "Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid." The phase 1, open-label, single-agent clinical trial of MCLA-145 is ongoing. The trial consists of a dose escalation phase, followed by a planned dose expansion phase. MCLA-145 is the first drug candidate co-developed under Merus' global collaboration and license agreement with Incyte (INCY).

08:11 EST Quanta's Medolife Rx announces results of study of CBD-based Muscle Rub - Medolife Rx announced that it has completed a study on its polarized cannabidiol muscle rub product, sold under the brand Aelia. The study reports that Aelia products are up to 604.7% stronger than with other non-polarized CBD products currently available on the market included in the test by analyzing the effectiveness of the product in reducing inflammation through the inhibition of cyclooxygenase-2 enzyme activity in the human body. The Company identified 3 best-selling muscle rubs with CBD to perform a comparison study with Aelia CBD Muscle Rub. Samples were tested using COX-2 fluorescent assay and read using SpectromaxID3. Data analyzing was supervised by third party scientist from BCN Biosciences, Elizabeh Singer, PhD. Data showed an increase from 97.7 up to 604.7% in inhibition of COX2 enzyme in the Aelia brand product when compared to other products in this study. The inhibition of the enzyme is believed to be an effective treatment for inflammation. CBD is being studied by various organizations for its potential role in COX-2 inhibition. Through the Company's polarization process, the potency of the CBD in Medolife's products is significantly increased, lending to the theory that inhibition of COX-2 enzymes by polarized CBD would result in the reduction of pain and inflammation. The Company plans to further investigate the effectiveness of the polarization technology in different applications of pain relief, chemotherapy, ribosome-based drug development, and more. Medolife also conducted studies testing the efficacy of polarized CBD, polarized Ibuprofen, the Company's lead drug candidate Escozine, and more. The results further suggest the success in which the polarization process increases the potency of active pharmaceutical ingredients.

08:10 EST Immutep announces no additional safety signals observed in INSIGHT-003 study - Immutep announces the first five patients have been treated in the INSIGHT-003 study. No additional safety signals have been observed in the study which is the first time a triple combination therapy consisting of eftilagimod alpha and an existing approved standard of care combination of chemotherapy and an anti-PD-1 therapy has been administered. INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy. The study will continue to recruit up to 20 patients with various solid tumours and additional results are expected in calendar year 2022.

08:09 EST Certara announces release of Simcyp Simulator Version 21 - Certara announced the release of Simcyp Simulator Version 21, which updates the Company's population-based modeling and simulation platform. The Simcyp Simulator is used throughout the drug development process to evaluate new drug formulations, determine first-in-human dosing, optimize clinical study design and predict drug-drug interactions. Certara's Simcyp physiologically-based pharmacokinetic Simulator models describe the behavior of drugs in different body tissues and include genetic, physiological and epidemiological databases that facilitate simulations in virtual populations. The Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drug approvals by the US Food and Drug Administration. These were achieved virtually, using PBPK modeling and simulation in lieu of performing clinical trials.

08:08 EST Onconova presents preliminary data on rigosertib in RDEB-associated SCC - Onconova Therapeutics announced that early preliminary data from an investigator-initiated Phase 2 open label trial of rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa were presented at the Austrian Society of Dermatology and Venerology Annual Conference 2021, which took place from November 25 - 27, 2021. RDEB is an ultra-rare condition caused by a lack of type VII collagen protein expression. Type VII collagen protein is responsible for anchoring the skin's inner layer to its outer layer, and its absence leads to extreme skin fragility and chronic wound formation in RDEB patients. Over time, many of these patients develop squamous cell carcinomas that typically arise in areas of chronic skin wounding and inflammation. Preclinical investigations demonstrated overexpression of polo like kinase 1 in RDEB-associated SCC tumor cells. These tumors show a highly aggressive, early metastasizing course, making them the primary cause of death for these patients, with a cumulative risk of death of 70% and 78.7% by age 45 and 55, respectively. These neoplasms show limited response rates of mostly short duration to conventional chemo- and radiotherapy as well as targeted therapy with epidermal growth factor and tyrosine kinase inhibitors. Data from the recent presentation are from a 24-year-old RDEB patient with a history of multiple, unresectable SCCs that were unresponsive to prior treatments including cemiplimab. Results showed that intravenously administered rigosertib had an acceptable safety profile and that the patient experienced sustained clinical and histological remission of all target lesions without signs of metastatic disease following 13 treatment cycles. The patient remains on study and the trial remains ongoing. The enrollment of additional patients is anticipated at sites in Salzburg, Austria; London, UK; and Philadelphia, Pennsylvania.

08:06 EST Cabot provides three year targets at investor day - Cabot provided a review of the company's updated growth strategy and financial targets at its investor day. The company announced a three year target adjusted EPS CAGR of 8%-12%. Additionally, the company introduced a three year target cumulative discretionary free cash flow of $1B. "Cabot is well-positioned for the next phase of growth and shareholder value creation as we execute our new 'Creating for Tomorrow' strategy. We will continue to drive our industry-leading businesses to achieve the next set of strategic objectives, which include growing our differentiated product lines, investing in higher margin applications and generating discretionary free cash flow in excess of $1 billion over the next three years. As we execute this strategy, we remain committed to maintaining an investment grade credit rating and returning capital to shareholders," said Sean Keohane, president and CEO.

08:06 EST On24 announces $50M share repurchase program - ON24 announced that its Board of Directors has authorized a share repurchase program where ON24 may purchase up to $50M of its common stock. "This share repurchase program reflects our confidence in ON24's long-term growth potential and strategy, which we believe is not reflected at the current market valuation. Our strong balance sheet allows us to implement this repurchase program as we continue to invest and build our platform for the future, as well as maintain flexibility to pursue new strategic opportunities," said Sharat Sharan, CEO of ON24. Under the repurchase program, ON24 may purchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The repurchase program has an 18-month term and ON24 expects repurchases under the program to extend over multiple quarters. The timing and number of shares repurchased under the program will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The repurchase program does not obligate ON24 to acquire any particular amount of common stock and may be modified, suspended, or discontinued at any time at the company's discretion. Repurchases under this program will be funded from the company's existing cash and cash equivalents or future cash flow. As of September 30 , ON24 had $399.7M in cash, cash equivalents, and marketable securities.

08:05 EST Bigg Digital Assets announces C$100,000 investment in TerraZero - BIGG Digital Assets is pleased to announce its strategic investment of CAD $100,000 in TerraZero Technologies Inc's recent private financing round. TerraZero Technologies' vision is to Develop, Acquire, and Finance the Metaverse's most promising companies, entrepreneurs, and developers. We build solutions to further enhance the Metaverse usability for greater community engagement, and to connect the real world to the Metaverse, for the creation of new economies and user experiences that will shape the future of web 3.0

08:04 EST Replimune Group appoints Christy Oliger to board of directors - Replimune Group announced the appointment of Christy Oliger to the Company's Board of Directors effective December 1, 2021. Previously Oliger was Senior Vice President of the Oncology Business Unit at Genentech responsible for all commercial activities in the US.

08:02 EST Meridian Bioscience's CFO Bryan Baldasare retiring - Meridian Bioscience CFO and Secretary Bryan Baldasare will retire from Meridian effective December 31. The company is engaging an executive search firm in the recruitment of a new CFO and appointed Julie Smith to the position of Senior VP, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022. Baldasare joined Meridian in 2000 and has served as CFO since July 2019.

07:55 EST Eneti announces contract for Wind Turbine Installation Vessel - Eneti announced that it entered into a binding agreement for the construction of one Wind Turbine Installation Vessel. The Company has exercised an option it held with Daewoo Shipbuilding and Marine Engineering for the construction of one WTIV. The contract price is $326.0 million, and the Vessel will be delivered early in the second quarter of 2025. The Vessel is an NG-16000X design by GustoMSC and includes a 2,600 Ton Leg Encircling Crane from Huisman Equipment B.V. of the Netherlands. The Vessel is capable of installing up to 20 Megawatt turbines at depths of up to 65 meters of water, and it can be adapted to operate on the alternate fuels of LNG or Ammonia.

07:48 EST Marcus Theatres announces 'strong' ticket sales for 'Spider-Man: No Way Home' - Marcus Theatres, a division of Marcus, announced that "Spider-Man: No Way Home" secured the most advance ticket sales for the company since "Avengers: End Game" in 2019. Tickets went on sale on "Spider Monday," November 29, and continue to be strong as guests make their way back to theatres. In just the first two days, an overwhelming 72% of the tickets sold were for UltraScreen DLX, SuperScreen DLX and IMAX auditoriums across the circuit.

07:47 EST II-VI announces proposed $990M notes offering - II-VI Incorporated announced that it plans to offer $990M aggregate principal amount of senior notes due 2029 in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended. The Notes will be guaranteed by each of the Company's material wholly owned domestic subsidiaries, subject to customary exceptions. The Company intends to use the proceeds from the offering of the Notes to fund the cash consideration, the repayment of certain indebtedness and certain fees and expenses in connection with the Company's previously announced pending business combination with Coherent, pursuant to an Agreement and Plan of Merger, dated March 25, 2021, by and among the Company, Coherent and Watson Merger Sub Inc., a wholly owned subsidiary of the Company.

07:41 EST Rekor Systems awarded patent for algorithm that detects traffic congestion - Rekor Systems has been awarded a patent for an algorithm that is helping cities take action against irregular traffic congestion with AI-based predictive insights. Irregular or non-recurring congestion refers to traffic congestion that is outside of the norm.U.S. Patent number 11,100,793 B2, granted for the company's "System and Method for Detection and Quantification of Irregular Traffic Congestion," is an algorithm that takes historical and real-time data from internal and external sources and turns it into a time-based, dynamic model that identifies anomalies in traffic patterns. The company's technology then generates a warning for users, such as traffic management centers, to investigate the root cause of the anomaly and take action to address it."We have deployed this algorithm in our technology on behalf of city, state and regional governments in the U.S., Israel and Sweden, along with private sector organizations, to identify congestion that is unusual compared to normal periods of heavier traffic like rush hour or holiday travel," said Shai Maron, vice president of engineering, Rekor. "Results in pilot programs and other deployments consistently show significant increases in the identification of irregular congestion, which allows us to alert customers in real-time so they can take immediate action to alleviate it. It also helps them learn more about their instances of non-recurring congestion so they can better plan for future roadway and infrastructure improvements."

07:37 EST Saia reports November LTL shipments per workday increased 3.7% - Saia is providing LTL shipment and tonnage data for the first two months of the fourth quarter. In October 2021, final LTL shipments per workday increased 1.3%, LTL tonnage per workday increased 9.7% and LTL weight per shipment increased 8.3% to 1,425 pounds compared to 1,316 pounds in October 2020. In November 2021, LTL shipments per workday increased 3.7%, LTL tonnage per workday increased 9.3% and LTL weight per shipment increased 5.4% to 1,413 pounds compared to 1,341 pounds in November 2020.

07:37 EST Hut 8 Mining provides production update for November - Hut 8 Mining provided a corporate update. In November, 265 Bitcoin were mined, resulting in an average production rate of 8.83 Bitcoin per day; 100% of the self-mined Bitcoin for the month of November were deposited into custody, total Bitcoin balance held in reserve is 5,242 as of November 30; the company completed the deployment of high-performance NVIDIA chips at Hut 8's site in Medicine Hat, Alberta. The company has deployed the NVIDIA CMPs to mine the Ethereum network via Luxor pool, and is receiving payouts in Bitcoin. Based on current mining economics this equates to approximately 1.8 - 2.0 additional Bitcoin per day. Hut 8 currently has an installed hashrate of approximately 1.7 EH/s, which includes the converted hashrate from its fleet of CMPs.

07:35 EST Xilio Therapeutics expects cash, cash equivalents to fund into 2024 - Cash and cash equivalents were $99.8M as of September 30, 2021, compared to $19.2M as of December 31, 2020. Cash and cash equivalents as of September 30, 2021 do not include $116.3M in estimated net proceeds from Xilio's October 2021 IPO. Xilio believes that its existing cash and cash equivalents, together with the net proceeds from its IPO, will enable it to fund its operating expenses and capital expenditure requirements into 2024.

07:35 EST SL Green Realty declares special dividend of $2.4392 per share - The Company announced that, as a result of extraordinary gains on asset dispositions in 2021, the board of directors has authorized and declared a special dividend of $2.4392 per share, comprised entirely of SLG's common stock, to be calculated as described below, which is payable on January 18, 2022 to stockholders of record on the Record Date. Stockholders will, therefore, receive a total dividend with a value of $2.75 per share, representing the sum of the monthly ordinary dividend and the special dividend. The number of shares issued for the special dividend will be calculated based on the volume weighted average trading price of SLG's common stock on the New York Stock Exchange between January 5-7, 2022. Stockholders can elect to receive the total dividend in the form of all cash or all stock, subject to proration if either option is oversubscribed.

07:34 EST Xilio Therapeutics announces anticipated milestones for 2022 - Xilio currently anticipates the following milestones in 2022: Initiation of a Phase 1/2 clinical trial to evaluate XTX202 in multiple solid tumor types in the first quarter of 2022; Presentation of preliminary data for the monotherapy cohort of the Phase 1/2 clinical trial evaluating XTX101 in patients with advanced solid tumors in the middle of 2022; Presentation of preliminary Phase 1 data for XTX202 in patients with multiple solid tumor types in the second half of 2022; Presentation of preliminary data from the combination cohort for the Phase 1/2 clinical trial evaluating XTX101 in patients with advanced solid tumors in the second half of 2022; and Submission of an IND for XTX301 in the second half of 2022.

07:33 EST Geron appoints Edward Koval as EVP and Chief Business Officer - Geron announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. "Ed Koval's business development expertise, extensive industry network and successful track record in corporate deal-making further strengthens our executive team," said John A. Scarlett, M.D., Chairman and Chief Executive Officer. "With top-line results from our IMerge Phase 3 trial in lower risk MDS expected 13 months from now, and an interim analysis of our ongoing IMpactMF Phase 3 trial in refractory myelofibrosis expected in 2024, Ed will be a key member of our executive management as we explore multiple strategies to build and accrete value in both our imetelstat and telomerase inhibitor franchises."

07:33 EST CME Group reports November ADV increased 20% to 23.1M contracts - Additional November product highlights compared to November 2020 include: Overall ADV increased 20%; Options ADV increased 59%.

07:31 EST Commercial Vehicle Group announces new Chief Commercial Officer - CVG announced that it has formed a new enterprise-wide global leadership position of Chief Commercial Officer, CCO, and has appointed Rich Tajer as its first CCO. Rich Tajer will also continue to be Business Leader of Electrical Systems. In this expanded role, Tajer will continue to report to Harold Bevis, President and Chief Executive Officer.

07:28 EST Novartis says 'confident' to grow sales at 4%+ CAGR through 2026 - Novartis will be holding an investor event to provide an overview of the company's progress in advancing its "industry-leading R&D engine," along with which Vas Narasimhan, CEO of Novartis, said: "Novartis has transformed to become a focused medicines company, building depth in our core therapeutic areas and strength across key technology platforms. We expect to continue delivering strong operational performance, with 4%+ CAGR through to 2026, driven by the momentum of our multi-billion dollar in-market growth drivers. Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs. We are building the foundation for long-term differential growth by investing in advanced technology platforms and data science. Novartis remains disciplined and shareholder focused in its capital allocation priorities, as we continue to deliver on our strategy" Novartis noted that Cosentyx, its "largest medicine by sales," showed topline results in moderate to severe hidradenitis suppurativa, or HS, a potential new indication. Two Phase 3 studies, SUNRISE and SUNSHINE, met their primary endpoint, with more patients treated with Cosentyx achieving a HS Clinical Response, compared with placebo, at week 16. The safety of Cosentyx in HS was consistent with the therapy's known safety profile. The trials are ongoing to 52 weeks and are expected to complete in H2 2022. Regulatory filings are planned for 2022. Phase 3 study starts planned or ongoing across 5 core therapeutic areas include studies in Cardio-Renal, IHD, Neuroscience, Oncology and Hematology, noted the company, which also provided an overview of its mid- and late-stage pipeline assets in five core therapeutic areas, highlighting Leqvio, pelacarsen, iptacopan, Cosentyx, ligelizumab, remibrutinib, ianalumab, LNA043, branaplam, Zolgensma, Kisqali, 177Lu-PSMA-617, sabatolimab, JDQ443, TNO155, Scemblix and NIS793.

07:22 EST Goodfood Market implements cost efficiency initiatives - The company said, "During the quarter, we have sought to identify and implement cost efficiency initiatives to drive margin improvement and align our resources with the agility required to capture leading online grocery market share with our on-demand growth platform. We embarked on a review of our organizational structure in light of the progressive completion and implementation of systems and improvement in processes coupled with aligning our workforce towards our future catalyst for growth, on-demand groceries, meal kits and ready-to-eat meals. As a result, we expect these initiatives to generate $10 to $15 million of annualized cost savings versus our annualized fourth quarter cost base."

07:21 EST Goodfood Market EVP, operations Gregory Christopher departs - Goodfood Market announced the departure of Gregory Christopher, EVP, Operations. President and COO, Neil Cuggy, will assume the role as the Company continues to focus investments into its rapidly growing on-demand grocery operations.

07:20 EST CareDx surpasses 80,000 organ transplant patient milestone - CareDx, The Transplant Company, announced that it has served over 80,000 organ transplant patients with AlloSure or AlloMap for their post-transplant care. "CareDx AlloSure and AlloMap are the most widely used donor-derived cell-free DNA, dd-cfDNA, tests used to measure organ transplant health. More than 90 percent of the nation's heart transplant centers use AlloMap Heart and 70 percent of kidney transplant centers use AlloSure Kidney," the company said. "CareDx's number one priority is to support patients through all aspects of their journey, from the moment they are put on the transplant list through their procedure and the lifetime of care they require after," said Reg Seeto, CEO and President of CareDx. "Our dream has always been one organ for the life of that patient, which requires active monitoring of the transplanted organ to identify risk of injury or a change in the immune state of the organ. Reaching this milestone of serving 80,000 transplant patients is a testament to the value of both AlloMap and AlloSure being incorporated into the standard management of heart, kidney, and lung transplant patients."

07:18 EST Surface Oncology to present clinical data from SRF617 Phase 1 trial at ESMO-IO - Surface Oncology announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress, ESMO-IO, 2021, to be held virtually from December 8 to 11, 2021. The poster includes new data from the ongoing Phase 1 study of SRF617, an antibody targeting CD39, as both a monotherapy and in combination, in patients with advanced solid tumors. Details of Surface's ESMO-IO poster presentation: Title: "First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients with advanced solid tumors."

07:18 EST Tanger Factory appoints Leslie Swanson as CFO, Andrew Wingrove as CCO - Tanger Factory promoted Leslie Swanson from Executive VP of Operations to COO and appointed Andrew Wingrove to the role of Chief Commercial Officer. Wingrove most recently served as the Senior Vice President for Travel at CLEAR and has held leadership positions at brands such as Bonobos, Delta Air Lines, and Macy's.

07:17 EST Enthusiast Gaming announces return of Pocket Gamer Connects event series - Enthusiast Gaming will relaunch its live event series Pocket Gamer Connects, with five live events spanning the globe in 2022, starting with PGC London from January 17-18. PGC provides an important platform for mobile gaming professionals to connect and interact, while providing industry-leading expert content and discussion around the mobile gaming space. PGC London 2022 will kick-off a year of live conferences that will be held in London, Seattle, Toronto, Helsinki, and Jordan. PGC London 2022 attendees can expect to meet over 800 companies from over 40 countries. More than 200 speakers will share insight and knowledge on topics including Revenue Roadmap, Mastering Multiplayer, and Live Ops. Speakers will include representatives from Voodoo, The National Film and Television School, Stillfront Group, Tencent, Netflix, King, and Square Enix.

07:16 EST Skylight announces pricing of public offering of 275K shares of Series A stock - Skylight Health Group announced the pricing of its public offering of 275,000 shares of its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares at a price to the public of US$21 per share. Gross proceeds from the offering are expected to be approximately US$5.8 million, before deducting offering expenses. The shares of Series A Preferred Stock are expected to start trading on the NASDAQ Capital Market on December 2, 2021, under the symbol "SLHGP". The offering is expected to close on or about December 6, 2021, subject to the satisfaction of customary closing conditions. The Benchmark Company, LLC acted as Sole Book Running Manager for the Offering. The underwriters have been granted a 30-day option to purchase up to 41,250 additional shares of Series A Preferred Stock from the Company, exercisable in whole or in part, solely to cover over-allotments, at the public offering price less the underwriting discount.

07:15 EST Uranium Royalty enters into strategic supply stream with CGN Global - Uranium Royalty has entered into a Supply Stream Agreement with CGN Global Uranium to purchase 500,000 pounds of U3O8 from CGN delivered at Cameco from 2023 through 2025 at a weighted average price of $47.71 per pound. 300,000 pounds of U3O8 will be delivered on October 20, 2023, and additional 100,000 pounds of U308 each to be delivered on June 14, 2024 and April 2, 2025. CGN Global is the overseas nuclear fuel business platform of China General Nuclear Power Group, the world's third largest, and China's biggest nuclear power operator with 25 units in operation.

07:13 EST OneWater Marine completes acquisition of T-H Marine - OneWater Marine announced that it has completed the previously announced acquisition of T-H Marine, a provider of branded marine parts and accessories. OneWater expects that the acquisition will significantly expand the Company's presence in the parts and accessories sector. The transaction is expected to more than double the annual revenue of OneWater's current business in the space. "We couldn't be more excited to welcome Jeff Huntley Sr. and his team into the OneWater family. This transaction meaningfully advances OneWater's strategic growth and diversification strategy and is expected to materially expand our addressable market in the parts and accessories business. T-H Marine will serve as an additional platform for growth with its strong pipeline in both product development and its own acquisition strategy, led by an experienced and capable team. With T-H Marine, we can now provide a more complete offering to our customers while continuing to drive growth and unlocking value for our shareholders," said Austin Singleton, Chief Executive Officer for OneWater.

07:13 EST Newmont sees attributable gold production of 6.2M ozs AISC of $1,050 per ounce - Newmont (NEM) announced its 2022 outlook with attributable gold production guidance of 6.2M million ounces and AISC of $1,050 per ounce at an $1,800 gold price assumption. Total gold production combined with other metals is expected to be 7.5 million gold equivalent ounces in 2022 and improve longer-term, with declining costs through investments in new, lower-cost production and benefits from Full Potential improvements. Attributable gold production : Production guidance is 6.2 million ounces for 2022 and is expected to improve to between 6.2 and 6.8 million ounces longer-term. Attributable gold equivalent ounce, GEO, production from other metals : Co-product GEO production guidance is 1.3 million ounces for 2022 and is expected to improve to between 1.4 to 1.6 million ounces longer-term. Total GEO production expected is 7.5 million ounces for 2022, improving to between 7.7 and 8.3 million ounces longer-term... Caterpillar (CAT) Strategic Alliance: Announced a strategic alliance with Caterpillar to deliver a fully connected, automated, zero carbon emitting, end-to-end mining system; includes an initial commitment of $100 million to deliver an autonomous electric haulage fleet of 16 vehicles at CC&V and 10 battery electric underground haul trucks at Tanami. "Newmont's outlook remains strong as we steadily increase production and improve costs over time from our global portfolio of world-class assets located in top-tier jurisdictions. In 2022 we expect to deliver approximately 7.5 million gold equivalent ounces, demonstrating the strength of our operations and proven operating model. We are entering a period of significant investment in our organic project pipeline, an important component in growing production, improving margins and extending mine life, and we remain focused on delivering long-term value to all of our stakeholders through our ongoing commitment to sustainable and responsible mining, " said Tom Palmer, Newmont President and Chief Executive Officer...Attributable gold production is expected to be stable at 6.0 to 6.8 million ounces across the five-year period. The 2022 outlook of 6.2 million ounces increases from 2021 due to increased production at Boddington and Ahafo. Production is expected to remain between 6.0 and 6.6 million ounces in 2023. This is supported by a steady base from our world class assets, and is further enhanced by the Company's other operating mines and our ownership in Nevada Gold Mines and Pueblo Viejo joint ventures. In 2024, production is expected to increase to between 6.2 and 6.8 million ounces longer-term through 2026 due to the inclusion of profitable production from Ahafo North and Tanami Expansion 2 and reaching higher gold grade at Penasquito.

07:13 EST Zentalis to host R&D day on December 16 - Zentalis Pharmaceuticals is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Zentalis' management team along with three Key Opinion Leaders will present preclinical science from multiple programs and clinical updates on ZN-d5, the Company's oral, selective BCL-2 inhibitor for hematologic malignancies, and ZN-e4, the Company's oral EGFR inhibitor for non-small cell lung carcinoma.

07:11 EST ReNew Power, L&T announce partnership in India - Larsen & Toubro and ReNew Power announced a partnership agreement to tap the emerging green hydrogen business in India. Under this agreement, L&T and ReNew will jointly develop, own, execute and operate green hydrogen projects in India

07:09 EST El Pollo Loco launches Loco Gifts and Gear store - El Pollo Loco announced the launch of Loco Gifts and Gear, its first-ever merch store. The online shop will bring El Pollo Loco's heritage and brand story to life through an exciting array of clothes, accessories and gear curated and handcrafted in a one-time exclusive collaboration with three Los Angeles-based Latino creators who embody El Pollo Loco's L.A. Mex spirit - David Flores, Rick Massie and Manny Silva. Beginning today, members of El Pollo Loco's Loco Rewards program will have early access to Loco Gifts and Gear to shop each artist's collection of exclusive apparel and gear. The site will open to the general public tonight at midnight.

07:09 EST Praxis Precision Medicines appoints Megan Sniecinski as CBO - Praxis Precision Medicines announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping down from his role as institute director of The Florey Institute of Neuroscience and Mental Health. Sniecinski was most recently chief business officer at BioCryst Pharmaceuticals, overseeing corporate development, program management and global supply chain.

07:07 EST Chesapeake announces $1B common stock, warrant repurchase authorization - Chesapeake Energy announced that its Board of Directors has authorized the repurchase of up to $1B in aggregate value of its common stock and/or warrants from time to time. Nick Dell'Osso, Chesapeake's President and CEO, stated "Generating sustainable cash flow and returning it to our shareholders is a foundational part of our strategy. We are pleased to build upon our previously announced base and variable dividend structure to include the ability to repurchase a significant amount of our outstanding equity. Despite the volatility in commodity markets, our cash flow projections remain robust, supporting a $1.75/share base dividend plus a variable dividend equal to 50% of our free cash flow. When combined, we estimate that total cash dividends to be paid to shareholders in 2022 will range from $800 million to $1 billion, based on our recent Outlook and the current commodity price environment. The addition of a $1 billion equity buyback program, which we expect to execute over the next 24 months, highlights the advantages of our disciplined capital allocation strategy, our resiliency through commodity price cycles, and our commitment to maintaining a capital reinvestment rate in our business to sustain our current cash flow over the long term."

07:06 EST Amdocs, G+D to provide eSIM managment for Orange Belgium - Amdocs and Giesecke+Devrient announced a joint collaboration to provide Orange Belgium's enterprise customers with the ability to order, activate and manage embedded SIM on their employees' devices. Orange Belgium is among the first service providers to launch eSIM for enterprises, bringing digital innovation to support their customers' journey to becoming fully digital. The eSIM Device Enablement Server marks the launch of eSIM support for enterprises and opens the way to new experiences for the enterprise consumer. Users will be able to easily and digitally add a new eSIM profile and switch between SIM profiles without the need to receive a plastic SIM card and manually insert it into the device, with the pre-integrated G+D/Amdocs solution responsible for integration to the billing system and device OEMs, orchestration and user interface management. By moving to digital, the solution will enable Orange Belgium's enterprise customers to reduce the cost and time in managing and delivering SIM cards, improving the overall experience for both the enterprise connectivity manager and the employee.

07:04 EST GXO Logistics, MYXfitness announce opening of Atlanta distribution center - GXO Logistics (GXO) and The Beachbody Company's (BODY) MYXfitness, announced the opening of a new distribution center in Atlanta to help meet growing ecommerce demand. The new facility in Atlanta is part of the GXO Direct distribution network, which provides shared warehouse space at locations across the U.S. with access to GXO's industry know-how and cutting-edge technology.

07:04 EST Acasti Pharma announces interim data meets primary endpoints in PK study - Acasti Pharma announced positive results for GTX-104 based on its interim analysis of the first 20 of 50 normal healthy subjects in its pivotal pharmacokinetic, PK, bridging study. GTX-104 met both primary endpoints for Maximum Concentration on Day 1 and Area Under the Concentration-Time Curve on Day 3, allowing the study to continue under the current infusion protocol to its completion. GTX-104 is a novel, aqueous formulation of nimodipine developed as an IV infusion for patients experiencing Subarachnoid Hemorrhage, or bleeding over the surface of the brain triggered by a ruptured aneurysm. The Company believes that the tight correlation of the primary endpoint data for the first 20 patients is a strong indication that GTX-104 could achieve comparable bioavailability with oral nimodipine in the full study cohort of 50 subjects. So far, there have been no serious adverse events observed, and only mild adverse events were reported in both groups such as headaches, that were resolved with common medications. "This interim data is very encouraging, as it suggests that our current infusion protocol is on track to meet the objectives for this pivotal PK study. As previously disclosed, we expect to report the final study results sometime in the first half of 2022. If the final study results are consistent with these interim results, we could proceed quickly to finalize the study design and protocol for the Phase 3 Safety Study of GTX-104 with the FDA, and initiate the study in the second half of 2022," commented Jan D'Alvise, Acasti's CEO. "Importantly, we believe the follow-up safety study has the potential to be relatively fast, low cost and low risk based on the favorable safety profile observed to date. Moreover, this clinical study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting our New Drug Application to the FDA."

07:03 EST Dollar General targets 1,000 pOpshelf locations by fiscal year end 2025 - "We are pleased with our third quarter results, and I want to thank our associates for their unwavering commitment to meeting the needs of our customers, communities, and each other," said Todd Vasos, Dollar General's CEO. "During the quarter, we made meaningful progress advancing our key initiatives, while continuing to successfully deliver for our customers, despite a challenging operating environment. We are excited today to announce our real estate growth plans for fiscal year 2022 , which consist of nearly 3,000 real estate projects in total, including 1,110 new stores. These plans include the acceleration of our pOpshelf store concept, as we expect to nearly triple our store count next year. Importantly, given the sustained and positive performance of our pOpshelf concept, we plan to further accelerate the pace of new store openings as we move ahead, targeting a total of approximately 1,000 pOpshelf locations by fiscal year end 2025. We are also excited to announce our plans to expand our footprint internationally for the first time, with plans to open up to ten stores in Mexico by the end of fiscal 2022, as we continue to lay the foundation for future growth. Overall, we remain focused on our mission of Serving Others, and are confident in our plans to drive long-term sustainable growth and value for our shareholders."

07:02 EST XORTX Therapeutics appoints Altasciences as CRO for clinical study - XORTX Therapeutics announces that it has appointed Altasciences as contract research organization for its planned Bridging pharmacokinetic study in support of the XRx-008 program for autosomal dominant polycystic kidney disease and XRx-101 for acute kidney injury associated with Coronavirus infection. The goal of the planned bridging pharmacokinetics study - XRX-OXY-101, is to characterize the increased bioavailability of oxypurinol in humans and follows after successful results in two animal models where increased bioavailability was demonstrated for this formulation.

06:59 EST UK's MHRA announces approval of COVID-19 treatment Xevudy - The UK's Medicines and Healthcare products Regulatory Agency said, "Another COVID-19 treatment, Xevudy, has today approved by the Medicines and Healthcare products Regulatory Agency after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease. This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government's independent expert scientific advisory body, the Commission on Human Medicines, making it the second monoclonal antibody therapeutic to be approved following Ronapreve. Developed by GSK (GSK) and Vir Biotechnology (VIR), sotrovimab is a single monoclonal antibody. The drug works by binding to the spike protein on the outside of the COVID-19 virus. This in turn prevents the virus from attaching to and entering human cells, so that it cannot replicate in the body. In a clinical trial, a single dose of the monoclonal antibody was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection. Based on the clinical trial data, sotrovimab is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible and within five days of symptom onset Like molnupiravir, it has been authorised for use in people who have mild to moderate COVID-19 infection and at least one risk factor for developing severe illness. Such risk factors include obesity, older age, diabetes mellitus, or heart disease. Unlike molnupiravir, sotrovimab is administered by intravenous infusion over 30 minutes. It is approved for individuals aged 12 and above who weigh more than 40kg. It is too early to know whether the omicron variant has any impact on sotrovimab's effectiveness but the MHRA will work with the company to establish this." Reference Link

06:52 EST The Buckle reports November net sales up 35.9% to $117.3M, SSS up 36% - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended November 27 increased 36% from comparable store net sales for the 4-week period ended November 28, 2020. Net sales for the 4-week fiscal month ended November 27 increased 35.9% to $117.3M from net sales of $86.3M for the prior year 4-week fiscal month ended November 28, 2020.

06:35 EST Toronto-Dominion raises quarterly dividend to C$0.89 per share - Payable on and after January 31, 2022, to shareholders of record at the close of business on January 10, 2022.

06:34 EST Toronto-Dominion to buy back up to 50M common shares - TD Bank Group announced that, subject to the approval of the Office of the Superintendent of Financial Institutions Canada and the Toronto Stock Exchange, it intends to launch a normal course issuer bid to repurchase for cancellation up to 50M of its common shares, representing approximately 2.7% of the 1,821,976,598 common shares issued and outstanding as of October 31, 2021. TD will file a notice of intention with the TSX in this regard.

06:19 EST SQZ Biotechnologies' lead cell therapy candidate generates clinical response - SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with SQZ Biotechnologies announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus positive - HPV16+ - solid tumors. In an abstract published by the European Society for Medical Oncology Immuno-Oncology Congress, the company reported that a highly treatment experienced patient in the highest-dose cohort demonstrated a radiographic response in conjunction with substantial increases in CD8 T cell tumor infiltration and PD-L1 expression - both markers of tumor inflammation. The cell therapy was generally well tolerated and no dose limiting toxicities were observed in the final monotherapy stage of the trial. The combination stage of the trial is enrolling with checkpoint inhibitors targeting the PD-(L)1 and CTLA-4 pathways. A total of 18 patients were treated across four cohorts and patients had an average of 3.5 prior lines of systemic cancer therapy. Across all cohorts the investigational therapy was generally well-tolerated, and no dose-limiting toxicities were observed. No grade 2 or higher treatment-related severe adverse events, or grade 3 adverse events, were observed in the highest-dose cohort. In the highest-dose cohort with five patients evaluable, one patient who had been heavily treated with PD-1 inhibitors before entering the trial demonstrated radiographic response as well as substantial increases in CD8 T cell tumor infiltration and PD-L1 expression. The highest-dose monotherapy stage continues enrollment to further characterize the investigational therapy in single agent settings.

06:10 EST Qutoutiao announces plan to implement ADS ratio change - Qutoutiao announced that it plans to change the ratio of its American Depositary Shares to its Class A ordinary shares, par value US$0.0001 per share, from the current ADS Ratio of four ADSs to one Class A ordinary share to a new ADS Ratio of two ADSs to five Class A ordinary shares. The company anticipates that the change in the ADS Ratio will be effective on or about December 10, 2021. For Qutoutiao's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split. Each ADS holder of record at the close of business on the date when the change in ADS Ratio is effective will be required to surrender and exchange every ten existing ADSs then held for one new ADS. The Bank of New York Mellon, as the depositary bank for Qutoutiao's ADS program, will arrange for the exchange of the current ADSs for the new ones. Qutoutiao's ADSs will continue to be traded on the Nasdaq Global Select Market under the symbol "QTT". No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements will distributed to the applicable ADS holders by the depositary bank. The change in the ADS Ratio will have no impact on Qutoutiao's underlying Class A ordinary shares, and no Class A ordinary shares will be issued or cancelled in connection with the change in the ADS Ratio. As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be equal to or greater than ten times the ADS trading price before the change.

06:06 EST Geo Group approves change in corporate structure - Geo Group's Board of Directors has unanimously approved a plan to terminate its Real Estate Investment Trust election and become a taxable C corporation, effective for the fiscal year ending December 31, 2021. The decision stems from the Board's evaluation of Geo's corporate tax structure and REIT status. The Board also voted unanimously to discontinue Geo's quarterly dividend. The change in corporate status from a REIT to a taxable C Corporation is expected to give Geo additional flexibility to allocate free cash flow towards reducing net recourse debt. In 2020, GEO reduced net recourse debt by approximately $100M, and in the first three quarters of 2021, Geo reduced net recourse debt by an additional $175M. As a result of Geo's restructuring to a taxable C corporation in FY21, during Q4, Geo expects to incur a one-time, non-cash deferred tax charge of approximately $75M. Geo also expects to incur approximately $34M in incremental income tax expense in Q4 due to the resulting higher corporate tax rate for 2021, including a catch-up tax expense of approximately $26M in connection with the first three quarters of 2021.

06:03 EST GMS Inc. CEO says 'well positioned' heading into 2022 - "I am pleased to report another very strong quarter for GMS," said John Turner, Jr., President and CEO. "Net sales again topped a billion dollars with record levels of net income and Adjusted EBITDA. Supply chain dynamics have led to all-time high levels of product inflation, which have been the principal driver of both sales growth and incremental profitability. That said, our relentless focus on customer service and the solid execution of our strategic priorities have enabled us to capture the benefits of both this heightened product inflation across our portfolio as well as continued strength in the residential market." Turner continued, "While commercial activity remains well below pre-COVID levels, we were pleased to see certain commercial projects that were previously on hold receive approvals to move forward. With other positive signs also emerging, we believe that we are very well positioned as we head into the next calendar year to benefit from an eventual commercial construction recovery."

06:02 EST BioRestorative Therapies files ten patent applications for lumbar disc disease - BioRestorative Therapies has filed ten patent applications related to its BRTX-100 program for treating chronic lumbar disc disease with the USPTO. These patent applications cover methodologies used to generate BRTX-100, a stem cell-based therapeutic engineered to treat patients suffering from chronic lumbar disc disease. BioRestorative currently is authorized by the FDA to commence a Phase 2 clinical trial using BRTX-100.

05:32 EST NanoVibronix announces accelerated sales for Painshield - NanoVibronix announced that sales of its Painshield device to the Veterans Administration, or VA, has been accelerating. Brian Murphy, CEO of Nanovibronix, stated, "Sales of our PainShield device to the VA commenced mid-summer, and we are pleased to report that adoption is happening at a relatively rapid pace in the first facilities where it is available. All indications appear to us to show that our revolutionary device is recognized as an effective treatment, as our devices are being prescribed by VA healthcare providers at an increasing rate to remedy pain suffered by so many of our veterans. Furthermore, we are experiencing higher than usual reorders of the disposables that accompany the device, which generally signals a high level of patient compliance and satisfaction. The VA is committed to finding better ways to manage pain, limit the risks of opioid therapy and address the growing epidemic of opioid misuse. As a non-opioid alternative, PainShield aligns directly with these goals."

05:23 EST Moderna announces revised COVID-19 vaccine supply agreement with UK government - Moderna announced a revised supply agreement with the UK government for up to 60M doses of Moderna's COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29M doses expected to be delivered in 2022 and up to 31M doses expected to be delivered in 2023. Under the agreement, the UK government retains a right to increase its purchases in 2022 and 2023 by up to 20% above the contracted volumes, or to decrease by the same amount.

05:19 EST WISeKey to launch new collection of art NFTs - WISeKey announced the launch of an international new collection of art NFTs during Art Basel Miami Beach week. The WISe.ART NFT gallery has opened online for the Miami Art Week with artists like Luca Bonfanti, Vika Kova, Marcella Moser, Mike Nwogugu and Pedro Sandoval. Artworks will go on sale on February 14, 2022.

05:14 EST Royal Dutch Shell commences $1.5B share buybacks from Permian sale - Royal Dutch Shell announced the commencement of up to $1.5B of share buybacks, being the first tranche of the $7B shareholder distributions from the sale of the company's Permian business in the United States. The form and timing for distributing the remaining $5.5B will be announced in early 2022. These distributions are in addition to our shareholder distributions in the range of 20%-30% of cash flow from operations. The company has entered into an arrangement with a broker to enable the purchase of A ordinary shares and/or B ordinary shares for a period up to and including January 28, 2022. The aggregate maximum consideration for the purchase of A ordinary shares and/or B ordinary shares is $1.5B. All shares repurchased as part of this arrangement will be cancelled. The maximum number of ordinary shares which may be purchased by the company under this arrangement is 687,166,438, which is the maximum pursuant to the authority granted by shareholders at the company's annual general meeting, less the number of ordinary shares that were repurchased by the company pursuant to the share buyback program announced on July 29. The shares bought back under this arrangement will be whichever of the A ordinary shares and/or B ordinary shares traded in the GBP denomination is economically the least expensive on a given trading day. The broker will make its trading decisions in relation to the company's securities independently of the company. The share buybacks will be carried out on the London Stock Exchange and/or on BATS and/or on Chi-X and will be effected within certain pre-set parameters.

05:06 EST CooTek to focus on Metaverse, NFT assets - CooTek announced that the company has been focusing on developing digital content and interactive game products related to Metaverse, and building up the digital content copyright system based on Non-Fungible Token, or NFT, cryptographic assets on blockchain. The company will establish its proprietary IP, technology and product systems, and deploy in the fields of Metaverse and NFT as the company's long-term development strategy.

04:55 EST Cars.com to replace DSP Group in the S&P 600 at open on 12/2 - Cars.com (CARS) will replace DSP Group (DSPG) in the S&P SmallCap 600. S&P MidCap 400 constituent Synaptics (SYNA) is acquiring DSP Group in a deal expected to be completed on December 2.

04:55 EST Bruker to replace KAR Auction in the S&P 400 at open on 12/2 - Bruker BioSciences Corp. (BRKR) will replace KAR Auction Services (KAR) in the S&P MidCap 400, and KAR Auction Services will replace Meredith Corp. (MDP) in the S&P SmallCap 600. Meredith is being acquired in a two-step transaction that is expected to be completed on or about December 1. KAR Auctions is more representative of the small-cap market space.